

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
11 August 2005 (11.08.2005)

PCT

(10) International Publication Number  
**WO 2005/073724 A1**

- (51) International Patent Classification<sup>7</sup>: **G01N 33/53**, 33/566, A01N 61/00, C12Q 1/68
- (21) International Application Number: PCT/US2005/002734
- (22) International Filing Date: 27 January 2005 (27.01.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/539,851 28 January 2004 (28.01.2004) US
- (71) Applicant (for all designated States except US): **EX-ELIXIS, INC.** [US/US]; 170 Harbor Way, P. O. Box 511, South San Francisco, CA 94083-0511 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **FRANCIS-LANG, Helen** [GB/US]; 1782 Pacific Avenue, Apt. 2, San Francisco, CA 94109 (US). **WINTER, Christopher G.** [US/US]; 641 Homer Avenue, Palo Alto, CA 94301 (US). **VENTURA, Richard Benn Abegania** [US/US]; 290 Bay Ridge Drive, Daly City, CA 94014 (US). **BJERKE, Margaret Lynn** [US/US]; 728 Alabama Street, #201, San Francisco, CA 94110 (US).
- (74) Agents: **SHAYESTEHEH, Laleh** et al.; Exelixis, Inc., P.O. Box 511, 170 Harbor Way, South San Francisco, CA 94083-0511 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MBCATS AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE

(57) Abstract: Human MBCAT genes are identified as modulators of the beta-catenin pathway and thus are therapeutic targets for disorders associated with defective beta-catenin function. Methods for identifying modulators of beta-catenin comprising screening for agents that modulate the activity of MBCAT are provided.

WO 2005/073724 A1

## MBCATS AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE

### REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. provisional patent application 60/539,851 filed 1/28/2004. The contents of the prior application are hereby incorporated in their entirety.

### BACKGROUND OF THE INVENTION

[0002] The *Drosophila Melanogaster* Armadillo/beta-catenin protein is implicated in multiple cellular functions. The protein functions in cell signaling via the Wingless (Wg)/Wnt signaling pathway. It also functions as a cell adhesion protein at the cell membrane in a complex with E-cadherin and alpha-catenin (Cox et al. (1996) J. Cell Biol. 134: 133-148; Godt and Tepass (1998) Nature 395: 387-391; White et al. (1998) J Cell Biol. 140:183-195). These two roles of beta -catenin can be separated from each other (Orsulic and Peifer (1996) J. Cell Biol. 134: 1283-1300; Sanson et al. (1996) Nature 383: 627-630).

[0003] In Wingless cell signaling, beta -catenin levels are tightly regulated by a complex containing APC, Axin, and GSK3 beta /SGG/ZW3 (Peifer et al. (1994) Development 120: 369-380).

[0004] The Wingless/ beta -catenin signaling pathway is frequently mutated in human cancers, particularly those of the colon. Mutations in the tumor suppressor gene APC, as well as point mutations in beta -catenin itself lead to the stabilization of the beta -catenin protein and inappropriate activation of this pathway.

[0005] The ability to manipulate the genomes of model organisms such as *Drosophila* provides a powerful means to analyze biochemical processes that, due to significant evolutionary conservation, have direct relevance to more complex vertebrate organisms. Due to a high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between these model organisms and mammals, identification of the involvement of novel genes in particular pathways and their functions in such model organisms can directly contribute to the understanding of the correlative pathways and methods of modulating them in mammals (see, for example, Mechler BM et al., 1985 EMBO J 4:1551-1557; Gateff E. 1982 Adv. Cancer Res. 37: 33-74; Watson KL., et al., 1994 J Cell Sci. 18: 19-33; Miklos GL, and Rubin GM. 1996 Cell

86:521-529; Wassarman DA, et al., 1995 *Curr Opin Gen Dev* 5: 44-50; and Booth DR. 1999 *Cancer Metastasis Rev.* 18: 261-284). For example, a genetic screen can be carried out in an invertebrate model organism having underexpression (e.g. knockout) or overexpression of a gene (referred to as a “genetic entry point”) that yields a visible phenotype. Additional genes are mutated in a random or targeted manner. When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a “modifier” involved in the same or overlapping pathway as the genetic entry point. When the genetic entry point is an ortholog of a human gene implicated in a disease pathway, such as beta-catenin, modifier genes can be identified that may be attractive candidate targets for novel therapeutics.

[0006] All references cited herein, including patents, patent applications, publications, and sequence information in referenced Genbank identifier numbers, are incorporated herein in their entireties.

#### SUMMARY OF THE INVENTION

[0007] We have discovered genes that modify the beta-catenin pathway in *Drosophila*, and identified their human orthologs, hereinafter referred to as Modifier of beta-catenin (MBCAT). The invention provides methods for utilizing these beta-catenin modifier genes and polypeptides to identify MBCAT-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired beta-catenin function and/or MBCAT function. Preferred MBCAT-modulating agents specifically bind to MBCAT polypeptides and restore beta-catenin function. Other preferred MBCAT-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress MBCAT gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).

[0008] MBCAT modulating agents may be evaluated by any convenient *in vitro* or *in vivo* assay for molecular interaction with an MBCAT polypeptide or nucleic acid. In one embodiment, candidate MBCAT modulating agents are tested with an assay system comprising an MBCAT polypeptide or nucleic acid. Agents that produce a change in the activity of the assay system relative to controls are identified as candidate beta-catenin modulating agents. The assay system may be cell-based or cell-free. MBCAT-modulating agents include MBCAT related proteins (e.g. dominant negative mutants, and biotherapeutics); MBCAT -specific antibodies; MBCAT -specific antisense oligomers and

other nucleic acid modulators; and chemical agents that specifically bind to or interact with MBCAT or compete with MBCAT binding partner (e.g. by binding to an MBCAT binding partner). In one specific embodiment, a small molecule modulator is identified using a binding assay. In specific embodiments, the screening assay system is selected from an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay.

**[0009]** In another embodiment, candidate beta-catenin pathway modulating agents are further tested using a second assay system that detects changes in the beta-catenin pathway, such as angiogenic, apoptotic, or cell proliferation changes produced by the originally identified candidate agent or an agent derived from the original agent. The second assay system may use cultured cells or non-human animals. In specific embodiments, the secondary assay system uses non-human animals, including animals predetermined to have a disease or disorder implicating the beta-catenin pathway, such as an angiogenic, apoptotic, or cell proliferation disorder (e.g. cancer).

**[0010]** The invention further provides methods for modulating the MBCAT function and/or the beta-catenin pathway in a mammalian cell by contacting the mammalian cell with an agent that specifically binds an MBCAT polypeptide or nucleic acid. The agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to a mammalian animal predetermined to have a pathology associated with the beta-catenin pathway.

### DETAILED DESCRIPTION OF THE INVENTION

**[0011]** In a screen to identify enhancers and suppressors of the Wg signaling pathway, we generated activated beta -catenin models in *Drosophila* based on human tumor data (Polakis (2000) Genes and Development 14: 1837-1851). We identified modifiers of the Wg pathway and identified their orthologs. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, MBCAT genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies associated with a defective beta-catenin signaling pathway, such as cancer. Table 1 (Example II) lists the modifiers and their orthologs.

**[0012]** In vitro and in vivo methods of assessing MBCAT function are provided herein. Modulation of the MBCAT or their respective binding partners is useful for understanding the association of the beta-catenin pathway and its members in normal and disease conditions and for developing diagnostics and therapeutic modalities for beta-catenin

related pathologies. MBCAT-modulating agents that act by inhibiting or enhancing MBCAT expression, directly or indirectly, for example, by affecting an MBCAT function such as enzymatic (e.g., catalytic) or binding activity, can be identified using methods provided herein. MBCAT modulating agents are useful in diagnosis, therapy and pharmaceutical development.

#### **Nucleic acids and polypeptides of the invention**

[0013] Sequences related to MBCAT nucleic acids and polypeptides that can be used in the invention are disclosed in Genbank (referenced by Genbank identifier (GI) or RefSeq number), shown in Table 1 and in the appended sequence listing.

[0014] The term "MBCAT polypeptide" refers to a full-length MBCAT protein or a functionally active fragment or derivative thereof. A "functionally active" MBCAT fragment or derivative exhibits one or more functional activities associated with a full-length, wild-type MBCAT protein, such as antigenic or immunogenic activity, enzymatic activity, ability to bind natural cellular substrates, etc. The functional activity of MBCAT proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Current Protocols in Protein Science (1998) Coligan *et al.*, eds., John Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below. In one embodiment, a functionally active MBCAT polypeptide is an MBCAT derivative capable of rescuing defective endogenous MBCAT activity, such as in cell based or animal assays; the rescuing derivative may be from the same or a different species. For purposes herein, functionally active fragments also include those fragments that comprise one or more structural domains of an MBCAT, such as a binding domain. Protein domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2). Methods for obtaining MBCAT polypeptides are also further described below. In some embodiments, preferred fragments are functionally active, domain-containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of an MBCAT. In further preferred embodiments, the fragment comprises the entire functionally active domain.

[0015] The term "MBCAT nucleic acid" refers to a DNA or RNA molecule that encodes an MBCAT polypeptide. Preferably, the MBCAT polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more

preferably 90%, and most preferably at least 95% sequence identity with human MBCAT. Methods of identifying orthologs are known in the art. Normally, orthologs in different species retain the same function, due to presence of one or more protein motifs and/or 3-dimensional structures. Orthologs are generally identified by sequence homology analysis, such as BLAST analysis, usually using protein bait sequences. Sequences are assigned as a potential ortholog if the best hit sequence from the forward BLAST result retrieves the original query sequence in the reverse BLAST (Huynen MA and Bork P, Proc Natl Acad Sci (1998) 95:5849-5856; Huynen MA *et al.*, Genome Research (2000) 10:1204-1210). Programs for multiple sequence alignment, such as CLUSTAL (Thompson JD *et al.*, 1994, Nucleic Acids Res 22:4673-4680) may be used to highlight conserved regions and/or residues of orthologous proteins and to generate phylogenetic trees. In a phylogenetic tree representing multiple homologous sequences from diverse species (e.g., retrieved through BLAST analysis), orthologous sequences from two species generally appear closest on the tree with respect to all other sequences from these two species. Structural threading or other analysis of protein folding (e.g., using software by ProCeryon, Biosciences, Salzburg, Austria) may also identify potential orthologs. In evolution, when a gene duplication event follows speciation, a single gene in one species, such as *Drosophila*, may correspond to multiple genes (paralogs) in another, such as human. As used herein, the term "orthologs" encompasses paralogs. As used herein, "percent (%) sequence identity" with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0a19 (Altschul *et al.*, J. Mol. Biol. (1997) 215:403-410) with all the search parameters set to default values. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. A % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported. "Percent (%) amino acid sequence similarity" is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.

- [0016] A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.
- [0017] Alternatively, an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, *Advances in Applied Mathematics* 2:482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981, *J. of Molec.Biol.*, 147:195-197; Nicholas et al., 1998, "A Tutorial on Searching Sequence Databases and Sequence Scoring Methods" ([www.psc.edu](http://www.psc.edu)) and references cited therein.; W.R. Pearson, 1991, *Genomics* 11:635-650). This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: *Atlas of Protein Sequences and Structure*, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA), and normalized by Gribskov (Gribskov 1986 *Nucl. Acids Res.* 14(6):6745-6763). The Smith-Waterman algorithm may be employed where default parameters are used for scoring (for example, gap open penalty of 12, gap extension penalty of two). From the data generated, the "Match" value reflects "sequence identity."
- [0018] Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence of an MBCAT. The stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (*e.g.*, *Current Protocol in Molecular Biology*, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook *et al.*, *Molecular Cloning*, Cold Spring Harbor (1989)). In some embodiments, a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of an MBCAT under high stringency hybridization conditions that are: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising 6X single strength citrate (SSC) (1X SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100 µg/ml herring sperm DNA; hybridization for 18-20 hours at 65° C

in a solution containing 6X SSC, 1X Denhardt's solution, 100  $\mu\text{g/ml}$  yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65° C for 1h in a solution containing 0.1X SSC and 0.1% SDS (sodium dodecyl sulfate).

[0019] In other embodiments, moderately stringent hybridization conditions are used that are: pretreatment of filters containing nucleic acid for 6 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500  $\mu\text{g/ml}$  denatured salmon sperm DNA; hybridization for 18-20h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100  $\mu\text{g/ml}$  salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55° C in a solution containing 2X SSC and 0.1% SDS.

[0020] Alternatively, low stringency conditions can be used that are: incubation for 8 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20  $\mu\text{g/ml}$  denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 37° C for 1 hour.

### **Isolation, Production, Expression, and Mis-expression of MBCAT Nucleic Acids and Polypeptides**

[0021] MBCAT nucleic acids and polypeptides are useful for identifying and testing agents that modulate MBCAT function and for other applications related to the involvement of MBCAT in the beta-catenin pathway. MBCAT nucleic acids and derivatives and orthologs thereof may be obtained using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art. In general, the particular use for the protein will dictate the particulars of expression, production, and purification methods. For instance, production of proteins for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes. Expression of proteins to be purified for screening or antibody production may require the addition of specific tags (*e.g.*, generation of fusion proteins). Overexpression of an MBCAT protein for assays used to assess MBCAT function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular

activities. Techniques for the expression, production, and purification of proteins are well known in the art; any suitable means therefore may be used (e.g., Higgins SJ and Hames BD (eds.) *Protein Expression: A Practical Approach*, Oxford University Press Inc., New York 1999; Stanbury PF et al., *Principles of Fermentation Technology*, 2<sup>nd</sup> edition, Elsevier Science, New York, 1995; Doonan S (ed.) *Protein Purification Protocols*, Humana Press, New Jersey, 1996; Coligan JE et al, *Current Protocols in Protein Science* (eds.), 1999, John Wiley & Sons, New York). In particular embodiments, recombinant MBCAT is expressed in a cell line known to have defective beta-catenin function. The recombinant cells are used in cell-based screening assay systems of the invention, as described further below.

**[0022]** The nucleotide sequence encoding an MBCAT polypeptide can be inserted into any appropriate expression vector. The necessary transcriptional and translational signals, including promoter/enhancer element, can derive from the native MBCAT gene and/or its flanking regions or can be heterologous. A variety of host-vector expression systems may be utilized, such as mammalian cell systems infected with virus (e.g. vaccinia virus, adenovirus, *etc.*); insect cell systems infected with virus (e.g. baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA. An isolated host cell strain that modulates the expression of, modifies, and/or specifically processes the gene product may be used.

**[0023]** To detect expression of the MBCAT gene product, the expression vector can comprise a promoter operably linked to an MBCAT gene nucleic acid, one or more origins of replication, and, one or more selectable markers (e.g. thymidine kinase activity, resistance to antibiotics, *etc.*). Alternatively, recombinant expression vectors can be identified by assaying for the expression of the MBCAT gene product based on the physical or functional properties of the MBCAT protein in *in vitro* assay systems (e.g. immunoassays).

**[0024]** The MBCAT protein, fragment, or derivative may be optionally expressed as a fusion, or chimeric protein product (i.e. it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection. A chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other using standard methods and expressing the chimeric product. A chimeric product may also be made by protein synthetic techniques, e.g. by use of a peptide synthesizer (Hunkapiller *et al.*, *Nature* (1984) 310:105-111).

[0025] Once a recombinant cell that expresses the MBCAT gene sequence is identified, the gene product can be isolated and purified using standard methods (*e.g.* ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis). Alternatively, native MBCAT proteins can be purified from natural sources, by standard methods (*e.g.* immunoaffinity purification). Once a protein is obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography.

[0026] The methods of this invention may also use cells that have been engineered for altered expression (mis-expression) of MBCAT or other genes associated with the beta-catenin pathway. As used herein, mis-expression encompasses ectopic expression, over-expression, under-expression, and non-expression (*e.g.* by gene knock-out or blocking expression that would otherwise normally occur).

#### **Genetically modified animals**

[0027] Animal models that have been genetically modified to alter MBCAT expression may be used in *in vivo* assays to test for activity of a candidate beta-catenin modulating agent, or to further assess the role of MBCAT in a beta-catenin pathway process such as apoptosis or cell proliferation. Preferably, the altered MBCAT expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control animals having normal MBCAT expression. The genetically modified animal may additionally have altered beta-catenin expression (*e.g.* beta-catenin knockout). Preferred genetically modified animals are mammals such as primates, rodents (preferably mice or rats), among others. Preferred non-mammalian species include zebrafish, *C. elegans*, and *Drosophila*. Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, *i.e.* mosaic animals (see, for example, techniques described by Jakobovits, 1994, *Curr. Biol.* 4:761-763.) or stably integrated into its germ line DNA (*i.e.*, in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.

[0028] Methods of making transgenic animals are well-known in the art (for transgenic mice see Brinster et al., *Proc. Nat. Acad. Sci. USA* 82: 4438-4442 (1985), U.S. Pat. Nos.

4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., and Hogan, B., *Manipulating the Mouse Embryo*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat. No., 4,945,050, by Sandford *et al.*; for transgenic *Drosophila* see Rubin and Spradling, *Science* (1982) 218:348-53 and U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. *et al.*, *A Universal Marker for Transgenic Insects* (1999) *Nature* 402:370-371; for transgenic Zebrafish see Lin S., *Transgenic Zebrafish*, *Methods Mol Biol.* (2000);136:375-3830); for microinjection procedures for fish, amphibian eggs and birds see Houdebine and Chourrout, *Experientia* (1991) 47:897-905; for transgenic rats see Hammer *et al.*, *Cell* (1990) 63:1099-1112; and for culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection see, e.g., *Teratocarcinomas and Embryonic Stem Cells, A Practical Approach*, E. J. Robertson, ed., IRL Press (1987)). Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. *et al.* (1997) *Nature* 385:810-813; and PCT International Publication Nos. WO 97/07668 and WO 97/07669).

[0029] In one embodiment, the transgenic animal is a “knock-out” animal having a heterozygous or homozygous alteration in the sequence of an endogenous MBCAT gene that results in a decrease of MBCAT function, preferably such that MBCAT expression is undetectable or insignificant. Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it. The transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species. For example, a mouse MBCAT gene is used to construct a homologous recombination vector suitable for altering an endogenous MBCAT gene in the mouse genome. Detailed methodologies for homologous recombination in mice are available (see Capecchi, *Science* (1989) 244:1288-1292; Joyner *et al.*, *Nature* (1989) 338:153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, *supra*; Pursel *et al.*, *Science* (1989) 244:1281-1288; Simms *et al.*, *Bio/Technology* (1988) 6:179-183). In a preferred embodiment, knock-out animals, such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been

knocked out (Claesson MH et al., (1994) *Scan J Immunol* 40:257-264; Declerck PJ et al., (1995) *J Biol Chem.* 270:8397-400).

**[0030]** In another embodiment, the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the MBCAT gene, e.g., by introduction of additional copies of MBCAT, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the MBCAT gene. Such regulatory sequences include inducible, tissue-specific, and constitutive promoters and enhancer elements. The knock-in can be homozygous or heterozygous.

**[0031]** Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene. One example of such a system that may be produced is the cre/loxP recombinase system of bacteriophage P1 (Lakso *et al.*, *PNAS* (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991) *Science* 251:1351-1355; U.S. Pat. No. 5,654,182). In a preferred embodiment, both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the transgene, and for sequential deletion of vector sequences in the same cell (Sun X et al (2000) *Nat Genet* 25:83-6).

**[0032]** The genetically modified animals can be used in genetic studies to further elucidate the beta-catenin pathway, as animal models of disease and disorders implicating defective beta-catenin function, and for *in vivo* testing of candidate therapeutic agents, such as those identified in screens described below. The candidate therapeutic agents are administered to a genetically modified animal having altered MBCAT function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered MBCAT expression that receive candidate therapeutic agent.

**[0033]** In addition to the above-described genetically modified animals having altered MBCAT function, animal models having defective beta-catenin function (and otherwise normal MBCAT function), can be used in the methods of the present invention. For

example, a beta-catenin knockout mouse can be used to assess, *in vivo*, the activity of a candidate beta-catenin modulating agent identified in one of the *in vitro* assays described below.

[0034] Preferably, the candidate beta-catenin modulating agent when administered to a model system with cells defective in beta-catenin function, produces a detectable phenotypic change in the model system indicating that the beta-catenin function is restored, i.e., the cells exhibit normal cell cycle progression.

### **Modulating Agents**

[0035] The invention provides methods to identify agents that interact with and/or modulate the function of MBCAT and/or the beta-catenin pathway. Modulating agents identified by the methods are also part of the invention. Such agents are useful in a variety of diagnostic and therapeutic applications associated with the beta-catenin pathway, as well as in further analysis of the MBCAT protein and its contribution to the beta-catenin pathway. Accordingly, the invention also provides methods for modulating the beta-catenin pathway comprising the step of specifically modulating MBCAT activity by administering an MBCAT-interacting or -modulating agent.

[0036] As used herein, an "MBCAT-modulating agent" is any agent that modulates MBCAT function, for example, an agent that interacts with MBCAT to inhibit or enhance MBCAT activity or otherwise affect normal MBCAT function. MBCAT function can be affected at any level, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In a preferred embodiment, the MBCAT - modulating agent specifically modulates the function of the MBCAT. The phrases "specific modulating agent", "specifically modulates", etc., are used herein to refer to modulating agents that directly bind to the MBCAT polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the MBCAT. These phrases also encompass modulating agents that alter the interaction of the MBCAT with a binding partner, substrate, or cofactor (e.g. by binding to a binding partner of an MBCAT, or to a protein/binding partner complex, and altering MBCAT function). In a further preferred embodiment, the MBCAT- modulating agent is a modulator of the beta-catenin pathway (e.g. it restores and/or upregulates beta-catenin function) and thus is also a beta-catenin-modulating agent.

[0037] Preferred MBCAT-modulating agents include small molecule compounds; MBCAT-interacting proteins, including antibodies and other biotherapeutics; and nucleic

acid modulators such as antisense and RNA inhibitors. The modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients. Techniques for formulation and administration of the compounds may be found in "Remington's Pharmaceutical Sciences" Mack Publishing Co., Easton, PA, 19<sup>th</sup> edition.

### **Small molecule modulators**

- [0038] Small molecules are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains. Chemical agents, referred to in the art as "small molecule" compounds are typically organic, non-peptide molecules, having a molecular weight up to 10,000, preferably up to 5,000, more preferably up to 1,000, and most preferably up to 500 daltons. This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the MBCAT protein or may be identified by screening compound libraries. Alternative appropriate modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for MBCAT-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948).
- [0039] Small molecule modulators identified from screening assays, as described below, can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the beta-catenin pathway. The activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing. Additionally, candidate clinical compounds are generated with specific regard to clinical and pharmacological properties. For example, the reagents may be derivatized and re-screened using *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

### **Protein Modulators**

- [0040] Specific MBCAT-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the beta-catenin pathway and related disorders, as well as in validation assays for other MBCAT-modulating agents. In a preferred embodiment, MBCAT-interacting proteins affect normal MBCAT function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In another embodiment, MBCAT-interacting proteins are useful in detecting and providing information about the function of MBCAT proteins, as is relevant to beta-catenin related disorders, such as cancer (e.g., for diagnostic means).
- [0041] An MBCAT-interacting protein may be endogenous, i.e. one that naturally interacts genetically or biochemically with an MBCAT, such as a member of the MBCAT pathway that modulates MBCAT expression, localization, and/or activity. MBCAT-modulators include dominant negative forms of MBCAT-interacting proteins and of MBCAT proteins themselves. Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous MBCAT-interacting proteins (Finley, R. L. et al. (1996) in *DNA Cloning-Expression Systems: A Practical Approach*, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp. 169-203; Fashema SF et al., *Gene* (2000) 250:1-14; Drees BL *Curr Opin Chem Biol* (1999) 3:64-70; Vidal M and Legrain P *Nucleic Acids Res* (1999) 27:919-29; and U.S. Pat. No. 5,928,868). Mass spectrometry is an alternative preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, *Nature* (2000) 405:837-846; Yates JR 3<sup>rd</sup>, *Trends Genet* (2000) 16:5-8).
- [0042] An MBCAT-interacting protein may be an exogenous protein, such as an MBCAT-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory; Harlow and Lane (1999) *Using antibodies: a laboratory manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). MBCAT antibodies are further discussed below.
- [0043] In preferred embodiments, an MBCAT-interacting protein specifically binds an MBCAT protein. In alternative preferred embodiments, an MBCAT-modulating agent binds an MBCAT substrate, binding partner, or cofactor.

### *Antibodies*

- [0044] In another embodiment, the protein modulator is an MBCAT specific antibody agonist or antagonist. The antibodies have therapeutic and diagnostic utilities, and can be

used in screening assays to identify MBCAT modulators. The antibodies can also be used in dissecting the portions of the MBCAT pathway responsible for various cellular responses and in the general processing and maturation of the MBCAT.

**[0045]** Antibodies that specifically bind MBCAT polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian ortholog of MBCAT polypeptide, and more preferably, to human MBCAT. Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')<sub>2</sub> fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Epitopes of MBCAT which are particularly antigenic can be selected, for example, by routine screening of MBCAT polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Natl. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol. 20:483-89; Sutcliffe et al., (1983) Science 219:660-66) to the amino acid sequence of an MBCAT. Monoclonal antibodies with affinities of  $10^8 \text{ M}^{-1}$  preferably  $10^9 \text{ M}^{-1}$  to  $10^{10} \text{ M}^{-1}$ , or stronger can be made by standard procedures as described (Harlow and Lane, *supra*; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577). Antibodies may be generated against crude cell extracts of MBCAT or substantially purified fragments thereof. If MBCAT fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of an MBCAT protein. In a particular embodiment, MBCAT-specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols.

**[0046]** The presence of MBCAT-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding MBCAT polypeptides. Other assays, such as radioimmunoassays or fluorescent assays might also be used.

**[0047]** Chimeric antibodies specific to MBCAT polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the

antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment. Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain ~10% murine sequences and ~90% human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).

**[0048]** MBCAT-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).

**[0049]** Other suitable techniques for antibody production involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors (Huse et al., Science (1989) 246:1275-1281). As used herein, T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, *supra*).

**[0050]** The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134). A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins

may be produced (U.S. Pat. No. 4,816,567). Antibodies to cytoplasmic polypeptides may be delivered and reach their targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. No. 6,086,900).

**[0051]** When used therapeutically in a patient, the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously. The therapeutically effective dose and dosage regimen is determined by clinical studies. Typically, the amount of antibody administered is in the range of about 0.1 mg/kg –to about 10 mg/kg of patient weight. For parenteral administration, the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle. Such vehicles are inherently nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used. The vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential. The antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml to about 10 mg/ml. Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).

#### ***Specific biotherapeutics***

**[0052]** In a preferred embodiment, an MBCAT-interacting protein may have biotherapeutic applications. Biotherapeutic agents formulated in pharmaceutically acceptable carriers and dosages may be used to activate or inhibit signal transduction pathways. This modulation may be accomplished by binding a ligand, thus inhibiting the activity of the pathway; or by binding a receptor, either to inhibit activation of, or to activate, the receptor. Alternatively, the biotherapeutic may itself be a ligand capable of activating or inhibiting a receptor. Biotherapeutic agents and methods of producing them are described in detail in U.S. Pat. No. 6,146,628.

**[0053]** When the MBCAT is a ligand, it may be used as a biotherapeutic agent to activate or inhibit its natural receptor. Alternatively, antibodies against MBCAT, as described in the previous section, may be used as biotherapeutic agents.

**[0054]** When the MBCAT is a receptor, its ligand(s), antibodies to the ligand(s) or the MBCAT itself may be used as biotherapeutics to modulate the activity of MBCAT in the beta-catenin pathway.

### Nucleic Acid Modulators

[0055] Other preferred MBCAT-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit MBCAT activity. Preferred nucleic acid modulators interfere with the function of the MBCAT nucleic acid such as DNA replication, transcription, translocation of the MBCAT RNA to the site of protein translation, translation of protein from the MBCAT RNA, splicing of the MBCAT RNA to yield one or more mRNA species, or catalytic activity which may be engaged in or facilitated by the MBCAT RNA.

[0056] In one embodiment, the antisense oligomer is an oligonucleotide that is sufficiently complementary to an MBCAT mRNA to bind to and prevent translation, preferably by binding to the 5' untranslated region. MBCAT-specific antisense oligonucleotides, preferably range from at least 6 to about 200 nucleotides. In some embodiments the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length. The oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.

[0057] In another embodiment, the antisense oligomer is a phosphothioate morpholino oligomer (PMO). PMOs are assembled from four different morpholino subunits, each of which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiarnidate intersubunit linkages. Details of how to make and use PMOs and other antisense oligomers are well known in the art (e.g. see WO99/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281; Summerton J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7:187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841).

[0058] Alternative preferred MBCAT nucleic acid modulators are double-stranded RNA species mediating RNA interference (RNAi). RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. Methods relating to the use of RNAi to silence genes in *C. elegans*, *Drosophila*, plants, and humans are known

in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, S. M., et al., Nature Rev. Genet. 2, 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, 239-245 (2001); Hamilton, A. et al., Science 286, 950-952 (1999); Hammond, S. M., et al., Nature 404, 293-296 (2000); Zamore, P. D., et al., Cell 101, 25-33 (2000); Bernstein, E., et al., Nature 409, 363-366 (2001); Elbashir, S. M., et al., Genes Dev. 15, 188-200 (2001); WO0129058; WO9932619; Elbashir SM, et al., 2001 Nature 411:494-498; Novina CD and Sharp P. 2004 Nature 430:161-164; Soutschek J et al 2004 Nature 432:173-178).

**[0059]** Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and man and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, *et al*, Current Concepts in Antisense Drug Design, J Med Chem. (1993) 36:1923-1937; Tonkinson JL *et al.*, Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents, Cancer Invest. (1996) 14:54-65). Accordingly, in one aspect of the invention, an MBCAT-specific nucleic acid modulator is used in an assay to further elucidate the role of the MBCAT in the beta-catenin pathway, and/or its relationship to other members of the pathway. In another aspect of the invention, an MBCAT-specific antisense oligomer is used as a therapeutic agent for treatment of beta-catenin-related disease states.

### Assay Systems

**[0060]** The invention provides assay systems and screening methods for identifying specific modulators of MBCAT activity. As used herein, an "assay system" encompasses all the components required for performing and analyzing results of an assay that detects and/or measures a particular event. In general, primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the MBCAT nucleic acid or protein. In general, secondary assays further assess the activity of an MBCAT modulating agent identified by a primary assay and may confirm that the

modulating agent affects MBCAT in a manner relevant to the beta-catenin pathway. In some cases, MBCAT modulators will be directly tested in a secondary assay.

[0061] In a preferred embodiment, the screening method comprises contacting a suitable assay system comprising an MBCAT polypeptide or nucleic acid with a candidate agent under conditions whereby, but for the presence of the agent, the system provides a reference activity (e.g. binding activity), which is based on the particular molecular event the screening method detects. A statistically significant difference between the agent-biased activity and the reference activity indicates that the candidate agent modulates MBCAT activity, and hence the beta-catenin pathway. The MBCAT polypeptide or nucleic acid used in the assay may comprise any of the nucleic acids or polypeptides described above.

### **Primary Assays**

[0062] The type of modulator tested generally determines the type of primary assay.

#### ***Primary assays for small molecule modulators***

[0063] For small molecule modulators, screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that recreates or retains the relevant biochemical reaction of the target protein (reviewed in Sittampalam GS *et al.*, *Curr Opin Chem Biol* (1997) 1:384-91 and accompanying references). As used herein the term "cell-based" refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction. The term "cell free" encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified or crude cellular extracts. Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (*e.g.*, receptor-ligand binding), transcriptional activity (*e.g.*, using a reporter gene), enzymatic activity (*e.g.*, via a property of the substrate), activity of second messengers, immunogenicity and changes in cellular morphology or other cellular characteristics. Appropriate screening assays may use a wide range of detection methods including fluorescent, radioactive, colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected.

[0064] Cell-based screening assays usually require systems for recombinant expression of MBCAT and any auxiliary proteins demanded by the particular assay. Appropriate

methods for generating recombinant proteins produce sufficient quantities of proteins that retain their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry provide preferred methods for determining protein-protein interactions and elucidation of protein complexes. In certain applications, when MBCAT-interacting proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting protein to the MBCAT protein may be assayed by various known methods such as substrate processing (e.g. ability of the candidate MBCAT-specific binding agents to function as negative effectors in MBCAT-expressing cells), binding equilibrium constants (usually at least about  $10^7 M^{-1}$ , preferably at least about  $10^8 M^{-1}$ , more preferably at least about  $10^9 M^{-1}$ ), and immunogenicity (e.g. ability to elicit MBCAT specific antibody in a heterologous host such as a mouse, rat, goat or rabbit). For enzymes and receptors, binding may be assayed by, respectively, substrate and ligand processing.

**[0065]** The screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of an MBCAT polypeptide, a fusion protein thereof, or to cells or membranes bearing the polypeptide or fusion protein. The MBCAT polypeptide can be full length or a fragment thereof that retains functional MBCAT activity. The MBCAT polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to another tag. The MBCAT polypeptide is preferably human MBCAT, or is an ortholog or derivative thereof as described above. In a preferred embodiment, the screening assay detects candidate agent-based modulation of MBCAT interaction with a binding target, such as an endogenous or exogenous protein or other substrate that has MBCAT-specific binding activity, and can be used to assess normal MBCAT gene function.

**[0066]** Suitable assay formats that may be adapted to screen for MBCAT modulators are known in the art. Preferred screening assays are high throughput or ultra high throughput and thus provide automated, cost-effective means of screening compound libraries for lead compounds (Fernandes PB, *Curr Opin Chem Biol* (1998) 2:597-603; Sundberg SA, *Curr Opin Biotechnol* 2000, 11:47-53). In one preferred embodiment, screening assays uses fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer. These systems offer means to monitor protein-protein or DNA-protein interactions in which the intensity of the signal emitted from dye-labeled molecules depends upon their interactions with partner

molecules (*e.g.*, Selvin PR, Nat Struct Biol (2000) 7:730-4; Fernandes PB, *supra*; Hertzberg RP and Pope AJ, Curr Opin Chem Biol (2000) 4:445-451).

**[0067]** A variety of suitable assay systems may be used to identify candidate MBCAT and beta-catenin pathway modulators (*e.g.* U.S. Pat. Nos. 5,550,019 and 6,133,437 (apoptosis assays); and U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434 (angiogenesis assays), among others). Specific preferred assays are described in more detail below.

**[0068]** G-protein-coupled receptors (GPCRs) comprise a large family of cell surface receptors that mediate a diverse array of biological functions. They selectively respond to a wide variety of extracellular chemical stimuli to activate specific signaling cascades. Assays may measure reporter gene activity or changes in intracellular calcium ions, or other second messengers (Durocher Y *et al.*, Anal Biochem (2000) 284: 316-326; Miller TR *et al.*, J Biomol Screen (1999) 4:249-258). Such assays may utilize chimeric G $\alpha$  proteins that will couple to many different GPCRs and thus facilitate "universal" screening assays (Coward P *et al.*, Anal Biochem (1999) 270:242-248; Milligan G and Rees S *et al.*, Trends Pharmacol Sci (1999) 20:118-124).

**[0069]** GPCRs exert their effects through heterotrimeric G proteins, which cycle between active GTP- and inactive GDP-bound forms. Receptors catalyze the activation of G proteins by promoting exchange of GDP for GTP, while G proteins catalyze their own deactivation through their intrinsic GTPase activity. GEFs accelerate GDP dissociation and GTP binding, while GAPs stimulate GTP hydrolysis to GDP. The same assays used to monitor GPCR activity may thus be applied to monitor the activity of GEFs or GAPs. Alternatively, GEF activity may be assayed by the release of labeled GDP from the appropriate GTPase or by the uptake of labelled GTP. GAP activity may be monitored via a GTP hydrolysis assay using labeled GTP (*e.g.*, Jones S *et al.*, Molec Biol Cell (1998) 9:2819-2837).

**[0070]** **Apoptosis assays.** Apoptosis or programmed cell death is a suicide program activated within the cell, leading to fragmentation of DNA, shrinkage of the cytoplasm, membrane changes and cell death. Apoptosis is mediated by proteolytic enzymes of the caspase family. Many of the altering parameters of a cell are measurable during apoptosis. Assays for apoptosis may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay. The TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis (Lazebnik *et al.*, 1994, Nature 371, 346), by following the incorporation of fluorescein-dUTP (Yonehara *et*

*al.*, 1989, *J. Exp. Med.* 169, 1747). Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., et al., 1998, *Blood* 15:4730-41). Other cell-based apoptosis assays include the caspase-3/7 assay and the cell death nucleosome ELISA assay. The caspase 3/7 assay is based on the activation of the caspase cleavage activity as part of a cascade of events that occur during programmed cell death in many apoptotic pathways. In the caspase 3/7 assay (commercially available Apo-ONE™ Homogeneous Caspase-3/7 assay from Promega, cat# 67790), lysis buffer and caspase substrate are mixed and added to cells. The caspase substrate becomes fluorescent when cleaved by active caspase 3/7. The nucleosome ELISA assay is a general cell death assay known to those skilled in the art, and available commercially (Roche, Cat# 1774425). This assay is a quantitative sandwich-enzyme-immunoassay which uses monoclonal antibodies directed against DNA and histones respectively, thus specifically determining amount of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. Mono and oligonucleosomes are enriched in the cytoplasm during apoptosis due to the fact that DNA fragmentation occurs several hours before the plasma membrane breaks down, allowing for accumulation in the cytoplasm. Nucleosomes are not present in the cytoplasmic fraction of cells that are not undergoing apoptosis. The Phospho-histone H2B assay is another apoptosis assay, based on phosphorylation of histone H2B as a result of apoptosis. Fluorescent dyes that are associated with phosphohistone H2B may be used to measure the increase of phosphohistone H2B as a result of apoptosis. Apoptosis assays that simultaneously measure multiple parameters associated with apoptosis have also been developed. In such assays, various cellular parameters that can be associated with antibodies or fluorescent dyes, and that mark various stages of apoptosis are labeled, and the results are measured using instruments such as Cellomics™ ArrayScan® HCS System. The measurable parameters and their markers include anti-active caspase-3 antibody which marks intermediate stage apoptosis, anti-PARP-p85 antibody (cleaved PARP) which marks late stage apoptosis, Hoechst labels which label the nucleus and are used to measure nuclear swelling as a measure of early apoptosis and nuclear condensation as a measure of late apoptosis, and TOTO-3 fluorescent dye which labels DNA of dead cells with high cell membrane permeability.

[0071] An apoptosis assay system may comprise a cell that expresses an MBCAT, and that optionally has defective beta-catenin function (e.g. beta-catenin is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the apoptosis assay system and changes in induction of apoptosis relative to controls where no test agent

is added, identify candidate beta-catenin modulating agents. In some embodiments of the invention, an apoptosis assay may be used as a secondary assay to test a candidate beta-catenin modulating agents that is initially identified using a cell-free assay system. An apoptosis assay may also be used to test whether MBCAT function plays a direct role in apoptosis. For example, an apoptosis assay may be performed on cells that over- or under-express MBCAT relative to wild type cells. Differences in apoptotic response compared to wild type cells suggests that the MBCAT plays a direct role in the apoptotic response. Apoptosis assays are described further in US Pat. No. 6,133,437.

- [0072] Cell proliferation and cell cycle assays.** Cell proliferation may be assayed via bromodeoxyuridine (BRDU) incorporation. This assay identifies a cell population undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA. Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino *et al.*, 1986, *Int. J. Cancer* 38, 369; Campana *et al.*, 1988, *J. Immunol. Meth.* 107, 79), or by other means.
- [0073]** Cell proliferation is also assayed via phospho-histone H3 staining, which identifies a cell population undergoing mitosis by phosphorylation of histone H3. Phosphorylation of histone H3 at serine 10 is detected using an antibody specific to the phosphorylated form of the serine 10 residue of histone H3. (Chadlee, D.N. 1995, *J. Biol. Chem* 270:20098-105). Cell Proliferation may also be examined using [<sup>3</sup>H]-thymidine incorporation (Chen, J., 1996, *Oncogene* 13:1395-403; Jeoung, J., 1995, *J. Biol. Chem.* 270:18367-73). This assay allows for quantitative characterization of S-phase DNA syntheses. In this assay, cells synthesizing DNA will incorporate [<sup>3</sup>H]-thymidine into newly synthesized DNA. Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter). Another proliferation assay uses the dye Alamar Blue (available from Biosource International), which fluoresces when reduced in living cells and provides an indirect measurement of cell number (Voytik-Harbin SL *et al.*, 1998, *In Vitro Cell Dev Biol Anim* 34:239-46). Yet another proliferation assay, the MTS assay, is based on in vitro cytotoxicity assessment of industrial chemicals, and uses the soluble tetrazolium salt, MTS. MTS assays are commercially available, for example, the Promega CellTiter 96<sup>®</sup> AQueous Non-Radioactive Cell Proliferation Assay (Cat.# G5421).
- [0074]** Cell proliferation may also be assayed by colony formation in soft agar, or clonogenic survival assay (Sambrook *et al.*, *Molecular Cloning*, Cold Spring Harbor

(1989)). For example, cells transformed with MBCAT are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.

[0075] Cell proliferation may also be assayed by measuring ATP levels as indicator of metabolically active cells. Such assays are commercially available, for example Cell Titer-Glo™, which is a luminescent homogeneous assay available from Promega.

[0076] Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW et al. (1986) *Int J Radiat Biol Relat Stud Phys Chem Med* 49:237-55). Cells transfected with an MBCAT may be stained with propidium iodide and evaluated in a flow cytometer (available from Becton Dickinson), which indicates accumulation of cells in different stages of the cell cycle.

[0077] Accordingly, a cell proliferation or cell cycle assay system may comprise a cell that expresses an MBCAT, and that optionally has defective beta-catenin function (e.g. beta-catenin is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where no test agent is added, identify candidate beta-catenin modulating agents. In some embodiments of the invention, the cell proliferation or cell cycle assay may be used as a secondary assay to test a candidate beta-catenin modulating agents that is initially identified using another assay system such as a cell-free assay system. A cell proliferation assay may also be used to test whether MBCAT function plays a direct role in cell proliferation or cell cycle. For example, a cell proliferation or cell cycle assay may be performed on cells that over- or under-express MBCAT relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the MBCAT plays a direct role in cell proliferation or cell cycle.

[0078] **Angiogenesis.** Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson). Accordingly, an angiogenesis assay system may comprise a cell that expresses an MBCAT, and that optionally has defective beta-catenin function (e.g. beta-catenin is over-expressed or under-expressed relative to wild-type

cells). A test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate beta-catenin modulating agents. In some embodiments of the invention, the angiogenesis assay may be used as a secondary assay to test a candidate beta-catenin modulating agents that is initially identified using another assay system. An angiogenesis assay may also be used to test whether MBCAT function plays a direct role in cell proliferation. For example, an angiogenesis assay may be performed on cells that over- or under-express MBCAT relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the MBCAT plays a direct role in angiogenesis. U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434, among others, describe various angiogenesis assays.

**[0079] Hypoxic induction.** The alpha subunit of the transcription factor, hypoxia inducible factor-1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in vitro. Under hypoxic conditions, HIF-1 stimulates the expression of genes known to be important in tumour cell survival, such as those encoding glycolytic enzymes and VEGF. Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with MBCAT in hypoxic conditions (such as with 0.1% O<sub>2</sub>, 5% CO<sub>2</sub>, and balance N<sub>2</sub>, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman®. For example, a hypoxic induction assay system may comprise a cell that expresses an MBCAT, and that optionally has defective beta-catenin function (e.g. beta-catenin is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the hypoxic induction assay system and changes in hypoxic response relative to controls where no test agent is added, identify candidate beta-catenin modulating agents. In some embodiments of the invention, the hypoxic induction assay may be used as a secondary assay to test a candidate beta-catenin modulating agents that is initially identified using another assay system. A hypoxic induction assay may also be used to test whether MBCAT function plays a direct role in the hypoxic response. For example, a hypoxic induction assay may be performed on cells that over- or under-express MBCAT relative to wild type cells. Differences in hypoxic response compared to wild type cells suggests that the MBCAT plays a direct role in hypoxic induction.

**[0080] Cell adhesion.** Cell adhesion assays measure adhesion of cells to purified adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate

modulating agents. Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2× final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.

**[0081]** Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate. Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.

**[0082]** High-throughput cell adhesion assays have also been described. In one such assay, small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off. In this assay, not only the binding specificity of the peptides and modulators against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques in situ on the microchip is measured (Falsey JR et al., *Bioconjug Chem.* 2001 May-Jun;12(3):346-53).

**[0083] Tubulogenesis.** Tubulogenesis assays monitor the ability of cultured cells, generally endothelial cells, to form tubular structures on a matrix substrate, which generally simulates the environment of the extracellular matrix. Exemplary substrates include Matrigel™ (Becton Dickinson), an extract of basement membrane proteins containing laminin, collagen IV, and heparin sulfate proteoglycan, which is liquid at 4° C and forms a solid gel at 37° C. Other suitable matrices comprise extracellular components such as collagen, fibronectin, and/or fibrin. Cells are stimulated with a pro-angiogenic stimulant, and their ability to form tubules is detected by imaging. Tubules can generally be detected after an overnight incubation with stimuli, but longer or shorter time frames

may also be used. Tube formation assays are well known in the art (e.g., Jones MK et al., 1999, *Nature Medicine* 5:1418-1423). These assays have traditionally involved stimulation with serum or with the growth factors FGF or VEGF. Serum represents an undefined source of growth factors. In a preferred embodiment, the assay is performed with cells cultured in serum free medium, in order to control which process or pathway a candidate agent modulates. Moreover, we have found that different target genes respond differently to stimulation with different pro-angiogenic agents, including inflammatory angiogenic factors such as TNF- $\alpha$ . Thus, in a further preferred embodiment, a tubulogenesis assay system comprises testing an MBCAT's response to a variety of factors, such as FGF, VEGF, phorbol myristate acetate (PMA), TNF- $\alpha$ , ephrin, etc.

**[0084] Cell Migration.** An invasion/migration assay (also called a migration assay) tests the ability of cells to overcome a physical barrier and to migrate towards pro-angiogenic signals. Migration assays are known in the art (e.g., Paik JH et al., 2001, *J Biol Chem* 276:11830-11837). In a typical experimental set-up, cultured endothelial cells are seeded onto a matrix-coated porous lamina, with pore sizes generally smaller than typical cell size. The matrix generally simulates the environment of the extracellular matrix, as described above. The lamina is typically a membrane, such as the transwell polycarbonate membrane (Corning Costar Corporation, Cambridge, MA), and is generally part of an upper chamber that is in fluid contact with a lower chamber containing pro-angiogenic stimuli. Migration is generally assayed after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Migration is assessed as the number of cells that crossed the lamina, and may be detected by staining cells with hemotoxylin solution (VWR Scientific, South San Francisco, CA), or by any other method for determining cell number. In another exemplary set up, cells are fluorescently labeled and migration is detected using fluorescent readings, for instance using the Falcon HTS FluoroBlok (Becton Dickinson). While some migration is observed in the absence of stimulus, migration is greatly increased in response to pro-angiogenic factors. As described above, a preferred assay system for migration/invasion assays comprises testing an MBCAT's response to a variety of pro-angiogenic factors, including tumor angiogenic and inflammatory angiogenic agents, and culturing the cells in serum free medium.

**[0085] Sprouting assay.** A sprouting assay is a three-dimensional *in vitro* angiogenesis assay that uses a cell-number defined spheroid aggregation of endothelial cells

("spheroid"), embedded in a collagen gel-based matrix. The spheroid can serve as a starting point for the sprouting of capillary-like structures by invasion into the extracellular matrix (termed "cell sprouting") and the subsequent formation of complex anastomosing networks (Korff and Augustin, 1999, J Cell Sci 112:3249-58). In an exemplary experimental set-up, spheroids are prepared by pipetting 400 human umbilical vein endothelial cells into individual wells of a nonadhesive 96-well plates to allow overnight spheroidal aggregation (Korff and Augustin: J Cell Biol 143: 1341-52, 1998). Spheroids are harvested and seeded in 900 $\mu$ l of methocel-collagen solution and pipetted into individual wells of a 24 well plate to allow collagen gel polymerization. Test agents are added after 30 min by pipetting 100  $\mu$ l of 10-fold concentrated working dilution of the test substances on top of the gel. Plates are incubated at 37°C for 24h. Dishes are fixed at the end of the experimental incubation period by addition of paraformaldehyde. Sprouting intensity of endothelial cells can be quantitated by an automated image analysis system to determine the cumulative sprout length per spheroid.

**[0086] *Primary assays for antibody modulators***

**[0087]** For antibody modulators, appropriate primary assays test is a binding assay that tests the antibody's affinity to and specificity for the MBCAT protein. Methods for testing antibody affinity and specificity are well known in the art (Harlow and Lane, 1988, 1999, *supra*). The enzyme-linked immunosorbant assay (ELISA) is a preferred method for detecting MBCAT-specific antibodies; others include FACS assays, radioimmunoassays, and fluorescent assays.

**[0088]** In some cases, screening assays described for small molecule modulators may also be used to test antibody modulators.

**[0089] *Primary assays for nucleic acid modulators***

**[0090]** For nucleic acid modulators, primary assays may test the ability of the nucleic acid modulator to inhibit or enhance MBCAT gene expression, preferably mRNA expression. In general, expression analysis comprises comparing MBCAT expression in like populations of cells (*e.g.*, two pools of cells that endogenously or recombinantly express MBCAT) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art. For instance, Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR (*e.g.*, using the TaqMan®, PE Applied Biosystems), or microarray analysis may be used to confirm that

MBCAT mRNA expression is reduced in cells treated with the nucleic acid modulator (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm DH and Guiseppi-Elie, A Curr Opin Biotechnol 2001, 12:41-47). Protein expression may also be monitored. Proteins are most commonly detected with specific antibodies or antisera directed against either the MBCAT protein or specific peptides. A variety of means including Western blotting, ELISA, or in situ detection, are available (Harlow E and Lane D, 1988 and 1999, *supra*).

[0091] In some cases, screening assays described for small molecule modulators, particularly in assay systems that involve MBCAT mRNA expression, may also be used to test nucleic acid modulators.

### Secondary Assays

[0092] Secondary assays may be used to further assess the activity of MBCAT-modulating agent identified by any of the above methods to confirm that the modulating agent affects MBCAT in a manner relevant to the beta-catenin pathway. As used herein, MBCAT-modulating agents encompass candidate clinical compounds or other agents derived from previously identified modulating agent. Secondary assays can also be used to test the activity of a modulating agent on a particular genetic or biochemical pathway or to test the specificity of the modulating agent's interaction with MBCAT.

[0093] Secondary assays generally compare like populations of cells or animals (*e.g.*, two pools of cells or animals that endogenously or recombinantly express MBCAT) in the presence and absence of the candidate modulator. In general, such assays test whether treatment of cells or animals with a candidate MBCAT-modulating agent results in changes in the beta-catenin pathway in comparison to untreated (or mock- or placebo-treated) cells or animals. Certain assays use "sensitized genetic backgrounds", which, as used herein, describe cells or animals engineered for altered expression of genes in the beta-catenin or interacting pathways.

### Cell-based assays

[0094] Cell based assays may detect endogenous beta-catenin pathway activity or may rely on recombinant expression of beta-catenin pathway components. Any of the aforementioned assays may be used in this cell-based format. Candidate modulators are

typically added to the cell media but may also be injected into cells or delivered by any other efficacious means.

### *Animal Assays*

- [0095] A variety of non-human animal models of normal or defective beta-catenin pathway may be used to test candidate MBCAT modulators. Models for defective beta-catenin pathway typically use genetically modified animals that have been engineered to mis-express (*e.g.*, over-express or lack expression in) genes involved in the beta-catenin pathway. Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc.
- [0096] In a preferred embodiment, beta-catenin pathway activity is assessed by monitoring neovascularization and angiogenesis. Animal models with defective and normal beta-catenin are used to test the candidate modulator's affect on MBCAT in Matrigel® assays. Matrigel® is an extract of basement membrane proteins, and is composed primarily of laminin, collagen IV, and heparin sulfate proteoglycan. It is provided as a sterile liquid at 4° C, but rapidly forms a solid gel at 37° C. Liquid Matrigel® is mixed with various angiogenic agents, such as bFGF and VEGF, or with human tumor cells which over-express the MBCAT. The mixture is then injected subcutaneously(SC) into female athymic nude mice (Taconic, Germantown, NY) to support an intense vascular response. Mice with Matrigel® pellets may be dosed via oral (PO), intraperitoneal (IP), or intravenous (IV) routes with the candidate modulator. Mice are euthanized 5 - 12 days post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel.
- [0097] In another preferred embodiment, the effect of the candidate modulator on MBCAT is assessed via tumorigenicity assays. Tumor xenograft assays are known in the art (see, *e.g.*, Ogawa K et al., 2000, *Oncogene* 19:6043-6052). Xenografts are typically implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a pre-existing tumor or from *in vitro* culture. The tumors which express the MBCAT endogenously are injected in the flank,  $1 \times 10^5$  to  $1 \times 10^7$  cells per mouse in a volume of 100  $\mu$ L using a 27gauge needle. Mice are then ear tagged and tumors are measured twice weekly. Candidate modulator treatment is initiated on the day the mean tumor weight reaches 100 mg. Candidate modulator is delivered IV, SC, IP, or PO by bolus administration. Depending upon the pharmacokinetics of each unique candidate

modulator, dosing can be performed multiple times per day. The tumor weight is assessed by measuring perpendicular diameters with a caliper and calculated by multiplying the measurements of diameters in two dimensions. At the end of the experiment, the excised tumors maybe utilized for biomarker identification or further analyses. For immunohistochemistry staining, xenograft tumors are fixed in 4% paraformaldehyde, 0.1M phosphate, pH 7.2, for 6 hours at 4°C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen.

**[0098]** In another preferred embodiment, tumorogenicity is monitored using a hollow fiber assay, which is described in U.S. Pat No. US 5,698,413. Briefly, the method comprises implanting into a laboratory animal a biocompatible, semi-permeable encapsulation device containing target cells, treating the laboratory animal with a candidate modulating agent, and evaluating the target cells for reaction to the candidate modulator. Implanted cells are generally human cells from a pre-existing tumor or a tumor cell line. After an appropriate period of time, generally around six days, the implanted samples are harvested for evaluation of the candidate modulator. Tumorogenicity and modulator efficacy may be evaluated by assaying the quantity of viable cells present in the macrocapsule, which can be determined by tests known in the art, for example, MTT dye conversion assay, neutral red dye uptake, trypan blue staining, viable cell counts, the number of colonies formed in soft agar, the capacity of the cells to recover and replicate in vitro, etc.

**[0099]** In another preferred embodiment, a tumorogenicity assay use a transgenic animal, usually a mouse, carrying a dominant oncogene or tumor suppressor gene knockout under the control of tissue specific regulatory sequences; these assays are generally referred to as transgenic tumor assays. In a preferred application, tumor development in the transgenic model is well characterized or is controlled. In an exemplary model, the "RIP1-Tag2" transgene, comprising the SV40 large T-antigen oncogene under control of the insulin gene regulatory regions is expressed in pancreatic beta cells and results in islet cell carcinomas (Hanahan D, 1985, Nature 315:115-122; Parangi S et al, 1996, Proc Natl Acad Sci USA 93: 2002-2007; Bergers G et al, 1999, Science 284:808-812). An "angiogenic switch," occurs at approximately five weeks, as normally quiescent capillaries in a subset of hyperproliferative islets become angiogenic. The RIP1-TAG2 mice die by age 14 weeks. Candidate modulators may be administered at a variety of stages, including just prior to the angiogenic switch (e.g., for a model of tumor prevention), during the growth of small tumors (e.g., for a model of intervention), or during the growth of large and/or invasive tumors (e.g., for a model of regression). Tumorogenicity and modulator efficacy

can be evaluating life-span extension and/or tumor characteristics, including number of tumors, tumor size, tumor morphology, vessel density, apoptotic index, etc.

#### **Diagnostic and therapeutic uses**

**[0100]** Specific MBCAT-modulating agents are useful in a variety of diagnostic and therapeutic applications where disease or disease prognosis is related to defects in the beta-catenin pathway, such as angiogenic, apoptotic, or cell proliferation disorders. Accordingly, the invention also provides methods for modulating the beta-catenin pathway in a cell, preferably a cell pre-determined to have defective or impaired beta-catenin function (e.g. due to overexpression, underexpression, or misexpression of beta-catenin, or due to gene mutations), comprising the step of administering an agent to the cell that specifically modulates MBCAT activity. Preferably, the modulating agent produces a detectable phenotypic change in the cell indicating that the beta-catenin function is restored. The phrase "function is restored", and equivalents, as used herein, means that the desired phenotype is achieved, or is brought closer to normal compared to untreated cells. For example, with restored beta-catenin function, cell proliferation and/or progression through cell cycle may normalize, or be brought closer to normal relative to untreated cells. The invention also provides methods for treating disorders or disease associated with impaired beta-catenin function by administering a therapeutically effective amount of an MBCAT -modulating agent that modulates the beta-catenin pathway. The invention further provides methods for modulating MBCAT function in a cell, preferably a cell pre-determined to have defective or impaired MBCAT function, by administering an MBCAT -modulating agent. Additionally, the invention provides a method for treating disorders or disease associated with impaired MBCAT function by administering a therapeutically effective amount of an MBCAT -modulating agent.

**[0101]** The discovery that MBCAT is implicated in beta-catenin pathway provides for a variety of methods that can be employed for the diagnostic and prognostic evaluation of diseases and disorders involving defects in the beta-catenin pathway and for the identification of subjects having a predisposition to such diseases and disorders.

**[0102]** Various expression analysis methods can be used to diagnose whether MBCAT expression occurs in a particular sample, including Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, and microarray analysis. (e.g., Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann

Med 2001, 33:142-147; Blohm and Guiseppi-Elie, Curr Opin Biotechnol 2001, 12:41-47). Tissues having a disease or disorder implicating defective beta-catenin signaling that express an MBCAT, are identified as amenable to treatment with an MBCAT modulating agent. In a preferred application, the beta-catenin defective tissue overexpresses an MBCAT relative to normal tissue. For example, a Northern blot analysis of mRNA from tumor and normal cell lines, or from tumor and matching normal tissue samples from the same patient, using full or partial MBCAT cDNA sequences as probes, can determine whether particular tumors express or overexpress MBCAT. Alternatively, the TaqMan® is used for quantitative RT-PCR analysis of MBCAT expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems).

**[0103]** Various other diagnostic methods may be performed, for example, utilizing reagents such as the MBCAT oligonucleotides, and antibodies directed against an MBCAT, as described above for: (1) the detection of the presence of MBCAT gene mutations, or the detection of either over- or under-expression of MBCAT mRNA relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of MBCAT gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by MBCAT.

**[0104]** Kits for detecting expression of MBCAT in various samples, comprising at least one antibody specific to MBCAT, all reagents and/or devices suitable for the detection of antibodies, the immobilization of antibodies, and the like, and instructions for using such kits in diagnosis or therapy are also provided.

**[0105]** Thus, in a specific embodiment, the invention is drawn to a method for diagnosing a disease or disorder in a patient that is associated with alterations in MBCAT expression, the method comprising: a) obtaining a biological sample from the patient; b) contacting the sample with a probe for MBCAT expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of the disease or disorder. Preferably, the disease is cancer. The probe may be either DNA or protein, including an antibody.

## EXAMPLES

[0106] The following experimental section and examples are offered by way of illustration and not by way of limitation.

I. Drosophila beta-catenin screens

[0107] Two dominant loss of function screens were carried out in *Drosophila* to identify genes that interact with the Wg cell signaling molecule, beta -catenin (Riggleman et al. (1990) Cell 63:549-560; Peifer et al. (1991) Development 111:1029-1043). Late stage activation of the pathway in the developing *Drosophila* eye leads to apoptosis (Freeman and Bienz (2001) EMBO reports 2: 157-162), whereas early stage activation leads to an overgrowth phenotype. We discovered that ectopic expression of the activated protein in the wing results in changes of cell fate into ectopic bristles and wing veins.

[0108] Each transgene was carried in a separate fly stock:

[0109] Stocks and genotypes were as follows:

[0110] eye overgrowth transgene: isow; P{3.5 eyeless-Gal4}; P{arm(S56F)-pExp-UAS)/TM6b;

[0111] eye apoptosis transgene: y w; P{arm(S56F)-pExp-GMR)/CyO; and

[0112] wing transgene: P{arm( $\Delta$ N)-pExp-VgMQ)/FM7c

[0113] In the first dominant loss of function screen, females of each of these three transgenes were crossed to a collection of males containing genomic deficiencies. Resulting progeny containing the transgene and the deficiency were then scored for the effect of the deficiency on the eye apoptosis, eye overgrowth, and wing phenotypes, i.e., whether the deficiency enhanced, suppressed, or had no effect on their respective phenotypes. All data was recorded and all modifiers were retested with a repeat of the original cross. Modifying deficiencies of the phenotypes were then prioritized according to how they modified each of the three phenotypes.

[0114] Transposons contained within the prioritized deficiencies were then screened as described. Females of each of the three transgenes were crossed to a collection of 4 types of transposons (3 piggyBac-based and 1 P-element-based). The resulting progeny containing the transgene and the transposon were scored for the effect of the transposon on their respective phenotypes. All data was recorded and all modifiers were retested with a repeat of the original cross. Modifiers of the phenotypes were identified as either members of the Wg pathway, components of apoptotic related pathways, components of cell cycle related pathways, or cell adhesion related proteins.

[0115] In the second dominant loss of function screen, females of the eye overgrowth transgene were crossed to males from a collection of 3 types of piggyBac-based transposons. The resulting progeny containing the transgene and the transposon were scored for the effect of the transposon on the eye overgrowth phenotype. All data was recorded and all modifiers were retested with a repeat of the original cross. Modifiers of the phenotypes were identified as either members of the Wg pathway, components of cell cycle related pathways, or cell adhesion related proteins. Modifiers of the wing phenotype were identified as members of the beta-catenin pathway. Orthologs of the modifiers are referred to herein as MBCAT.

## II. Analysis of Table 1

[0116] BLAST analysis (Altschul et al., *supra*) was employed to identify orthologs of *Drosophila* modifiers. The columns "MBCAT symbol", and "MBCAT name aliases" provide a symbol and the known name abbreviations for the Targets, where available, from Genbank. "MBCAT RefSeq\_NA or GI\_NA", "MBCAT GI\_AA", "MBCAT NAME", and "MBCAT Description" provide the reference DNA sequences for the MBCATs as available from National Center for Biology Information (NCBI), MBCAT protein Genbank identifier number (GI#), MBCAT name, and MBCAT description, all available from Genbank, respectively. The length of each amino acid is in the "MBCAT Protein Length" column.

[0117] Names and Protein sequences of *Drosophila* modifiers of beta-catenin from screen (Example I), are represented in the "Modifier Name" and "Modifier GI\_AA" column by GI#, respectively.

Table 1

MBCAT symbol	MBCAT name aliases	MBCAT RefSeq_NA or GI_NA	MBCAT NA SEQ ID NO	MBCAT GI_AA	MBCAT AA SEQ ID NO	MBCAT name	MBCAT description	MBCAT protein length	Modifier name	Modifier gi_aa
GNA11	guanine nucleotide binding protein (G protein), alpha 11 (Gq class) guanine nucleotide-binding protein, Gq class, GNA11 GNA-11 GNA11	NM_002067 NM_152294	1	4504037	6	guanine nucleotide binding protein (G protein), alpha 11 (Gq class)	heterotrimeric G-protein GTPase	359	Galpha49B	24653107

GNA14	guanine nucleotide binding protein (G protein), alpha 14 guanine nucleotide-binding protein 14 GNA14	NM_004297	2	4758444	7	guanine nucleotide binding protein (G protein), alpha 14	protein binding; signal transducer; heterotrimeric G-protein GTPase	355	Galpha49B	24653107
GNA15	GNA15 GNA16 guanine nucleotide binding protein (G protein), alpha 15 (Gq class)	NM_002068	3	4504039	8	guanine nucleotide binding protein (G protein), alpha 15 (Gq class)	heterotrimeric G-protein GTPase;	374	Galpha49B	24653107
GNAQ	guanine nucleotide binding protein (G protein), q polypeptide G-ALPHA-q GNAQ	NM_002072	4	4504045	9	guanine nucleotide binding protein (G protein), q polypeptide	receptor signaling protein; heterotrimeric G-protein GTPase	359	Galpha49B	24653107
LOC346329	na similar to Guanine nucleotide-binding protein, alpha-11 subunit (GL2) LOC346329	XM_294195	5	37538265	10	similar to Guanine nucleotide-binding protein, alpha-11 subunit (GL2)	na	355	Galpha49B	24653107

### III. High-Throughput In Vitro Fluorescence Polarization Assay

[0118] Fluorescently-labeled MBCAT peptide/substrate are added to each well of a 96-well microtiter plate, along with a test agent in a test buffer (10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6). Changes in fluorescence polarization, determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc), relative to control values indicates the test compound is a candidate modifier of MBCAT activity.

### IV. High-Throughput In Vitro Binding Assay.

[0119] <sup>33</sup>P-labeled MBCAT peptide is added in an assay buffer (100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl<sub>2</sub>, 1% glycerol, 0.5% NP-40, 50 mM beta-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors) along with a test agent to the wells of a Neutralite-avidin coated assay plate and incubated at 25°C for 1 hour. Biotinylated substrate is then added to each well and incubated for 1 hour. Reactions are stopped by washing with PBS, and counted in a scintillation counter. Test agents that cause a

difference in activity relative to control without test agent are identified as candidate beta-catenin modulating agents.

V. Immunoprecipitations and Immunoblotting

[0120] For coprecipitation of transfected proteins,  $3 \times 10^6$  appropriate recombinant cells containing the MBCAT proteins are plated on 10-cm dishes and transfected on the following day with expression constructs. The total amount of DNA is kept constant in each transfection by adding empty vector. After 24 h, cells are collected, washed once with phosphate-buffered saline and lysed for 20 min on ice in 1 ml of lysis buffer containing 50 mM Hepes, pH 7.9, 250 mM NaCl, 20 mM -glycerophosphate, 1 mM sodium orthovanadate, 5 mM p-nitrophenyl phosphate, 2 mM dithiothreitol, protease inhibitors (complete, Roche Molecular Biochemicals), and 1% Nonidet P-40. Cellular debris is removed by centrifugation twice at  $15,000 \times g$  for 15 min. The cell lysate is incubated with 25  $\mu$ l of M2 beads (Sigma) for 2 h at 4 °C with gentle rocking.

[0121] After extensive washing with lysis buffer, proteins bound to the beads are solubilized by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane and blotted with the indicated antibodies. The reactive bands are visualized with horseradish peroxidase coupled to the appropriate secondary antibodies and the enhanced chemiluminescence (ECL) Western blotting detection system (Amersham Pharmacia Biotech).

VI. Expression analysis

[0122] All cell lines used in the following experiments are NCI (National Cancer Institute) lines, and are available from ATCC (American Type Culture Collection, Manassas, VA 20110-2209). Normal and tumor tissues are obtained from Impath, UC Davis, Clontech, Stratagene, Ardaís, Genome Collaborative, and Ambion.

[0123] TaqMan® analysis is used to assess expression levels of the disclosed genes in various samples.

[0124] RNA is extracted from each tissue sample using Qiagen (Valencia, CA) RNeasy kits, following manufacturer's protocols, to a final concentration of 50ng/ $\mu$ l. Single stranded cDNA is then synthesized by reverse transcribing the RNA samples using random hexamers and 500ng of total RNA per reaction, following protocol 4304965 of Applied Biosystems (Foster City, CA).

- [0125] Primers for expression analysis using TaqMan® assay (Applied Biosystems, Foster City, CA) are prepared according to the TaqMan® protocols, and the following criteria: a) primer pairs are designed to span introns to eliminate genomic contamination, and b) each primer pair produced only one product. Expression analysis is performed using a 7900HT instrument.
- [0126] TaqMan® reactions are carried out following manufacturer's protocols, in 25 µl total volume for 96-well plates and 10 µl total volume for 384-well plates, using 300nM primer and 250 nM probe, and approximately 25ng of cDNA. The standard curve for result analysis is prepared using a universal pool of human cDNA samples, which is a mixture of cDNAs from a wide variety of tissues so that the chance that a target will be present in appreciable amounts is good. The raw data are normalized using 18S rRNA (universally expressed in all tissues and cells).
- [0127] For each expression analysis, tumor tissue samples are compared with matched normal tissues from the same patient. A gene is considered overexpressed in a tumor when the level of expression of the gene is 2 fold or higher in the tumor compared with its matched normal sample. In cases where normal tissue is not available, a universal pool of cDNA samples is used instead. In these cases, a gene is considered overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type is greater than 2 times the standard deviation of all normal samples (i.e.,  $\text{Tumor} - \text{average}(\text{all normal samples}) > 2 \times \text{STDEV}(\text{all normal samples})$  ).
- [0128] A modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed. A decrease in tumor growth confirms therapeutic utility of the modulator. Prior to treating a patient with the modulator, the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression of the gene targeted by the modulator. The expression data for the gene(s) can also be used as a diagnostic marker for disease progression. The assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other available detection method.

## WHAT IS CLAIMED IS:

1. A method of identifying a candidate beta-catenin pathway modulating agent, said method comprising the steps of:
  - (a) providing an assay system comprising an MBCAT polypeptide or nucleic acid;
  - (b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and
  - (c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as a candidate beta-catenin pathway modulating agent.
2. The method of Claim 1 wherein the assay system comprises cultured cells that express the MBCAT polypeptide.
3. The method of Claim 2 wherein the cultured cells additionally have defective beta-catenin function.
4. The method of Claim 1 wherein the assay system includes a screening assay comprising an MBCAT polypeptide, and the candidate test agent is a small molecule modulator.
5. The method of Claim 4 wherein the assay is a binding assay.
6. The method of Claim 1 wherein the assay system is selected from the group consisting of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.
7. The method of Claim 1 wherein the assay system includes a binding assay comprising an MBCAT polypeptide and the candidate test agent is an antibody.

8. The method of Claim 1 wherein the assay system includes an expression assay comprising an MBCAT nucleic acid and the candidate test agent is a nucleic acid modulator.

9. The method of claim 8 wherein the nucleic acid modulator is an antisense oligomer.

10. The method of Claim 8 wherein the nucleic acid modulator is a PMO.

11. The method of Claim 1 additionally comprising:

(d) administering the candidate beta-catenin pathway modulating agent identified in (c) to a model system comprising cells defective in beta-catenin function and, detecting a phenotypic change in the model system that indicates that the beta-catenin function is restored.

12. The method of Claim 11 wherein the model system is a mouse model with defective beta-catenin function.

13. A method for modulating a beta-catenin pathway of a cell comprising contacting a cell defective in beta-catenin function with a candidate modulator that specifically binds to an MBCAT polypeptide, whereby beta-catenin function is restored.

14. The method of claim 13 wherein the candidate modulator is administered to a vertebrate animal predetermined to have a disease or disorder resulting from a defect in beta-catenin function.

15. The method of Claim 13 wherein the candidate modulator is selected from the group consisting of an antibody and a small molecule.

16. The method of Claim 1, comprising the additional steps of:

(d) providing a secondary assay system comprising cultured cells or a non-human animal expressing MBCAT ,

(e) contacting the secondary assay system with the test agent of (b) or an agent derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity; and

(f) detecting an agent-biased activity of the second assay system,  
wherein a difference between the agent-biased activity and the reference activity of the second assay system confirms the test agent or agent derived therefrom as a candidate beta-catenin pathway modulating agent,  
and wherein the second assay detects an agent-biased change in the beta-catenin pathway.

17. The method of Claim 16 wherein the secondary assay system comprises cultured cells.

18. The method of Claim 16 wherein the secondary assay system comprises a non-human animal.

19. The method of Claim 18 wherein the non-human animal mis-expresses a beta-catenin pathway gene.

20. A method of modulating beta-catenin pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds an MBCAT polypeptide or nucleic acid.

21. The method of Claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the beta-catenin pathway.

22. The method of Claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.

23. A method for diagnosing a disease in a patient comprising:  
obtaining a biological sample from the patient;  
contacting the sample with a probe for MBCAT expression;  
comparing results from step (b) with a control;  
determining whether step (c) indicates a likelihood of disease.

24. The method of claim 23 wherein said disease is cancer.

EX05-001patentin.txt  
SEQUENCE LISTING

<110> EXELIXIS, INC.

<120> MBCATS AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE

<130> EX05-001C-PC

<150> US 60/539,851

<151> 2004-01-28

<160> 10

<170> PatentIn version 3.2

<210> 1

<211> 1540

<212> DNA

<213> Homo sapiens

<400> 1

gccctcggcc ccgggccggc ccgccccgcc tcggcccgcc cctggcgagc cgccgggtcc	60
ccgctcggcc ggtggccgag gccggagggc cgcgccgggc ggcggccgag gcggtccgg	120
ccagggccgg gccgggggcc gggggcggc ggcgggcagg cggccgcgtc ggccggggcc	180
gggacgatga ctctggagtc catgatggcg tgttgccgta gcgatgaggt gaaggagtcc	240
aagcggatca acgccgagat cgagaagcag ctgcggcggg acaagcgcga cgcccggcgc	300
gagctcaagc tgctgctgct cggcacgggc gagagcggga agagcacggt catcaagcag	360
atgcgcatca tccacggcgc cggctactcg gaggaggaca agcgcggctt caccaagctc	420
gtctaccaga acatcttcac cgccatgcag gccatgatcc gggccatgga gacgctcaag	480
atcctctaca agtacgagca gaacaaggcc aatgcgctcc tgatccggga ggtggacgtg	540
gagaaggatga ccaccttca gcatcagtac gtcagtgcca tcaagaccct gtgggaggac	600
ccgggcatcc aggaatgcta cgaccgcagg cgcgagtacc agctctccga ctctgccaag	660
tactacctga ccgacgttga ccgcatcgcc accttgggct acctgcccac ccagcaggac	720
gtgctgcggg tccgcgtgcc caccaccggc atcatcgagt accttttca cctggagaac	780
atcatcttcc ggatggtgga tgtggggggc cagcggtcgg agcggaggaa gtggatccac	840
tgctttgaga acgtgacatc catcatgttt ctctgcgcc tcagcgaata cgaccaagtc	900
ctggtggagt cggacaacga gaaccgatg gaggagagca aagccctgtt ccggaccatc	960
atcacctacc cctggttcca gaactcctcc gtcacctctt tctcaaca gaaggacctg	1020
ctggaggaca agatcctgta ctgcacctg gtggactact tccccgagtt cgatggtccc	1080
cagcgggagc cccaggcggc gcgggagttc atcctgaaga tgttcgtgga cctgaacccc	1140
gacagcgaca agatcatcta ctcacacttc acgtgtgcca ccgacacgga gaacatccgc	1200
ttcgtgttcg cggccgtgaa ggacaccatc ctgcagctca acctcaagga gtacaacctg	1260
gtctgagcgc cccaggccca gggagacggg atggagacac ggggcaggac cttccttcca	1320
cggagcctgc gctgccgggc gggggcgct gccgagtccg ggccggggct ctgcccggg	1380

## EX05-001patentin.txt

aggagatttt ttttttttca tttttttaac aaatggtttt tatttcacag ttatcagggg 1440  
 atgtacatct ctccctccgt acacttcgcg caccttctca ccttttgta acggcaaagg 1500  
 cagccttttt ctggccttga cttatggctc gcttttttct 1540

<210> 2  
 <211> 1953  
 <212> DNA  
 <213> Homo sapiens

<400> 2  
 ctgCGgtcac tgctgaggtt ttcagaactt tccaggcaaa ggccagccag gtcctttgcc 60  
 tccaaccac tccgcgcta cctcccgcct ggggacaccc ctaggccag gagatcctac 120  
 tctccccga gcaccgacgt tccaactcgt ctgCGcccc gactgctgtc cggtcctgt 180  
 gccaagggg gcgCGcatct tcccggggcc agcaacgctc ccaacttctc gactcgcct 240  
 cctcctccc agagcgagag tggggcggg tgagcccga tccggggtgc actcgagcgt 300  
 tcccagcgt cggcattcac cccgcctcag agccgacttt cgaaggggga ttgagcctcg 360  
 gaggtccagg cgtcttact caaagctca gtcgGcccc gtcttttctt tccacacccc 420  
 tgtgcccgtc gcatgctggc cgggtgagcg gccgggcca ggattcgggt gcccggggccc 480  
 gcgctgcccc gtcgggtact gagctgagcg caccatggcc ggctgctgct gcctgtccgc 540  
 ggaggagaag gagtcgagc gcatcagcgc ggagatcgag cgacagcttc gtcgggacaa 600  
 gaaggacgcg cgccgtgagc ttaagctgct gctgctggga actggtgaaa gtgggaaaag 660  
 cacctttatc aagcagatga gaattatcca tgggtctggt tacagcgacg aagacagaaa 720  
 ggggttcacg aagctggttt accaaaacat attcaccgcc atgcaagcca tgatcagagc 780  
 gatggacacg ctaaggatac agtatgtgtg tgaacagaat aaggaaaatg cccagataat 840  
 cagagaagtg gaagtggaca aggtctccat gctctccagg gagcaggtgg aggccatcaa 900  
 gcagctctgg caagatccag gcatccagga gtgttacgac aggaggagg agtaccagct 960  
 gtcggactct gccaaatatt acctgactga cattgaccgc atcgccacac catcattcgt 1020  
 gcctaccaa caagatgtgc ttcgCGtccg agtgcccacc accggcatca ttgagtatcc 1080  
 attgacttg gaaaacatca tctttcggat ggtggatggt ggtggccaac gatcggaaag 1140  
 acggaagtgg attcactgct ttgagagtgt cacctccatt attttcttg ttgctctgag 1200  
 tgaatatgac caggtcctgg ctgagtgta caacgagaat cgcatggaag agagcaaagc 1260  
 cttatttaa accatcatca cctaccctg gtttctgaat tcgtctgtga ttttattctt 1320  
 gaacaagaag gatcttttg aagagaaaat catgtactct catctaatta gctatttccc 1380  
 agaatacaca ggaccgaaac aggatgtcag agctgccaga gactttatcc tgaagcttta 1440  
 ccaagatcag aatcctgaca aagagaaagt catctactct cacttcacat gtgctacaga 1500  
 tacagacaat attcGctttg tgtttgctgc tgtcaaagac acaattctac agctaaacct 1560  
 aagggattc aacctgtct aaaagctgct gccactcct cccctataac agaagatgtg 1620  
 atttgcaaac tccttgtttt atttgcaagt gcttctgaca tcaccagagc cagccccatg 1680

## EX05-001patentin.txt

ccaggaacta	aggatgtcat	gtagatcgtg	gggacagaga	tgggtgatgg	aacttggaag	1740
atatttgagt	ttaccaacat	actttaaaag	tccttacatc	ccaaattgtg	tttataatta	1800
ttttcttgac	ttttggctat	aagattttgt	gtaatttttg	aatttggtgt	tttctagaat	1860
ttttaaaagc	cactttgatt	tagttttaa	tatgtttaa	aatagcgatt	aaaattatgt	1920
aagcaaggaa	aaaaaaaaa	aaaaaaaaa	aaa			1953

<210> 3  
 <211> 2060  
 <212> DNA  
 <213> Homo sapiens

<400> 3						
tgttcccagc	actcaagcct	tgccaccgcc	gagccgggct	tcctgggtgt	ttcaggcaag	60
gaagtctagg	tccctggggg	gtgacccccca	aggaaaaggc	agcctccctg	cgcacccggt	120
tgcccggagc	cctctccagg	gccggctggg	ctggggggtg	ccctggccag	caggggcccg	180
ggggcgatgc	caccgggtgc	cgactgaggc	caccgcacca	tggcccgctc	gctgacctgg	240
cgctgctgcc	cctggtgcct	gacggaggat	gagaaggccg	ccgcccgggt	ggaccaggag	300
atcaacagga	tcctcttga	gcagaagaag	caggaccgcg	gggagctgaa	gctgctgctt	360
ttgggcccag	gcgagagcgg	gaagagcacc	ttcatcaagc	agatgcggat	catccacggc	420
gccggctact	cggaggagga	gcgcaagggc	ttccggcccc	tggtctacca	gaacatcttc	480
gtgtccatgc	gggcatgat	cgaggccatg	gagcggctgc	agattccatt	cagcaggccc	540
gagagcaagc	accacgctag	cctggtcatg	agccaggacc	cctataaagt	gaccacgttt	600
gagaagcgtc	acgctcggc	catgcagtgg	ctgtggaggg	atgccggcat	ccgggcctgc	660
tatgagcgtc	ggcgggaatt	ccacctgctc	gattcagccg	tgtactacct	gtcccacctg	720
gagcgcata	ccgaggaggg	ctacgtcccc	acagctcagg	acgtgctccg	cagccgcatg	780
cccaccactg	gcatcaacga	gtactgcttc	tccgtgcaga	aaaccaacct	gcggatcgtg	840
gacgtcgggg	gccagaagtc	agagcgtaag	aatggatcc	attgtttcga	gaacgtgatc	900
gccctcatct	acctggcctc	actgagtga	tacgaccagt	gcctggagga	gaacaaccag	960
gagaaccgca	tgaaggagag	cctcgcattg	tttgggacta	tcctggaact	accctggttc	1020
aaaagcacat	ccgtcatcct	ctttctcaac	aaaaccgaca	tcctggagga	gaaaatcccc	1080
acctcccacc	tggtactcta	tttcccagt	ttccagggcc	ctaagcagga	tgctgaggca	1140
gccaagaggt	tcatcctgga	catgtacacg	aggatgtaca	ccgggtgcgt	ggacggcccc	1200
gagggcagca	agaagggcgc	acgatccccga	cgcttttca	gccactacac	atgtgccaca	1260
gacacacaga	acatccgcaa	ggtcttcaag	gacgtgcggg	actcgggtgct	cgcccgctac	1320
ctggacgaga	tcaacctgct	gtgaccacag	ccccacctgg	ggcaggcggc	accggcgggc	1380
gggtgggagg	tgggagtggc	tgcagggacc	ctagtgtcct	ggtctatctc	tccagcctcg	1440
gcccacacgc	aagggagtcg	ggggacggcc	cgctgctggc	cgctctcttc	tctgcctctc	1500

## EX05-001patentin.txt

accaggacag cgcgggggca ggggtactcct gcccttgctt gactcagttt ccctcctttg 1560  
aaaggggaagg agcaaaacgg ccatttgggg tgccaggggtg gatgaaaagg tgaagaaatc 1620  
aggggattga gacttggggtg ggtgggcatc tctcaggagc cccatctccg ggcgtgtcac 1680  
ctcctgggca gggttctggg accctctgtg ggtgacgcac accctgggat ggggctagta 1740  
gagccttcag ggccttcgg gcgtggactc tggcgactc tagtggacag gagaaggaac 1800  
gccttcagg aacctgtgga ctaggggtgc agggacttcc ctttgcaagg ggtaacagac 1860  
cgctggaaaa cactgtcact ttcagagctc ggtggctcac agcgtgtcct gccccggttt 1920  
gcgagcagaga gaaatcgcg cccacaagca tccccatcc cttgcaggct gggggctggg 1980  
catgctgcat cttaaccttt tgtatttatt ccctcacctt ctgcagggtc ccgtgcgggc 2040  
tgaaattaa gatttcttag 2060

<210> 4  
<211> 2188  
<212> DNA  
<213> Homo sapiens

<400> 4  
aggggggtgcc ggcgggggctg cagcggaggc actttggaag aatgactctg gagtccatca 60  
tggcgtgctg cctgagcgag gaggccaagg aagcccggcg gatcaacgac gagatcgagc 120  
ggcagctccg cagggacaag cgggacgcc gccgggagct caagctgctg ctgctcggga 180  
caggagagag tggcaagagt acgtttatca agcagatgag aatcatccat gggtcaggat 240  
actctgatga agataaaagg ggcttcacca agctggtgta tcagaacatc ttcacggcca 300  
tgaggccat gatcagagcc atggacacac tcaagatccc atacaagtat gagcacaata 360  
aggctcatgc acaattagtt cgagaagttg atgtggagaa ggtgtctgct tttgagaatc 420  
catatgtaga tgcaataaag agtttatgga atgatcctgg aatccaggaa tgctatgata 480  
gacgacgaga atatcaatta tctgactcta ccaaatacta tcttaatgac ttggaccgcg 540  
tagctgacct tgcctacctg cctacgcaac aagatgtgct tagagttcga gtccccacca 600  
cagggatcat cgaatacccc tttgacttac aaagtgtcat tttcagaatg gtcgatgtag 660  
ggggccaaag gtcagagaga agaaaatgga tacactgctt tgaaaatgtc acctctatca 720  
tgtttctagt agcgttagt gaatatgatc aagtctcgt ggagtcagac aatgagaacc 780  
gaatggagga aagcaaggct ctcttagaa caattatcac ataccctgg ttccagaact 840  
cctcggttat tctgttctta aacaagaaag atcttctaga ggagaaaatc atgtattccc 900  
atctagtcga ctacttcca gaatatgatg gaccccagag agatgcccag gcagcccag 960  
aattcattct gaagatgttc gtggacctga acccagacag tgacaaaatt atctactccc 1020  
acttcacgtg cgccacagac accgagaata tccgctttgt ctttgctgcc gtcaaggaca 1080  
ccatcctcca gttgaacctg aaggagtaca atctggtcta attgtgcctc ctagacacct 1140  
gccctgccct tcctgggtgg gctattgaag atacacaaga gggactgtat ttctgtggaa 1200  
aacaatttgc ataatactaa tttattgccc tcctggactc tgtgtgagcg tgtccacaga 1260

## EX05-001patentin.txt

gttttagta aatattatga ttttatttaa actattcaga ggaaaaacag aggatgctga 1320  
 agtacagtcc cagcacattt cctctctatc ttttttttag gcaaaacctt gtgactcagt 1380  
 gtattttaa ttctcagtca tgcactcaca aagataagac ttgtttcttt ctgtctctct 1440  
 ctctttttct tttctatgga gcaaaacaaa gctgatttcc cttttttctt cccccgctaa 1500  
 ttcatacctc cctcctgatg tttttcccag gttacaatgg cctttatcct agttccattc 1560  
 ttgggtcaagt ttttctctca aatgatacag tcaggacaca tcgttcgatt taagccatca 1620  
 tcagcttaat ttaagtttgt agtttttgct gaaggattat atgtattaat acttacggtt 1680  
 ttaaatgtgt tgctttggat acacacatag tttctttttt aatagaatat actgtcttgt 1740  
 ctcaacttgg actgggacag tggatgccca tctaaaagtt aagtgtcatt tcttttagat 1800  
 gtttaccttc agccatagct tgattgctca gagaaatag cagaaggcag gatcaaagac 1860  
 acacaggagt cttttctttt gaaatgccac gtgccattgt ctttcctccc ttctttgctt 1920  
 ctttttctta ccctctcttt caattgcaga tgccaaaaaa gatgccaaca gacactacat 1980  
 taccctaag gctgctacc agaacctttt tataggttgt tcttaatttt tttgttggtg 2040  
 ttgttcaagc ttttcctttc ttttttttct tagtgtttgg gccacgattt taaaatgact 2100  
 tttattatgg gtatgtggtg ccaaagctgg ctttttgtca aataaaatga atacgaactt 2160  
 aaaaaataaa aaaaaaaaaa aaaaaaaaaa 2188

<210> 5  
 <211> 1068  
 <212> DNA  
 <213> Homo sapiens

<400> 5  
 atgactctgg agtccatgat ggcgtgttgc ctgagcgata aggtgaagga gtccaagcgg 60  
 atcaacgccg agatccagaa gcagctgcgg ggggacaagc gcgacgcccg gcgccagctc 120  
 aagctgctgc tgctcctcac gggcgagagc ggggaagagca ctttcatcaa gcagatgcgc 180  
 atcatccatg gcgcccggta ctaggaggag gacaaaaggg gcttcaccaa gctcgtctac 240  
 cagaacattt tcaccgccat gcaggccatg atccgggcca tggagacgct gaagatcctc 300  
 tacaagtgg agcagaacaa ggccaatgcg ctccagatcc gagaggtgga cgtggagaag 360  
 gtgaccacct ttgagcatcg gtacgtcagc gccatcaaga ccctgtggga cgaccccggc 420  
 atccacgagt gctacgaccg caggcgcgag taccagctct cggactcggc caagtactgc 480  
 gtgaccgacg tagactgcat cgccacctcg agctacctgc ccaccagca ggacgtgctg 540  
 cgggtccgcg tgcccaccac cggcgtcttc gacctggaga acatcatctt caggatggcg 600  
 gatgttgggg gacagcggtc ggcgcagagg aagtggatcc actgctttga gaacctgacg 660  
 tccatcccgt ttctcgtcgc cctcagtga tacgaccaag tcctggtgga gtcggacaac 720  
 gagaaccgga tggaggagag caaagccctg ttccggacca tcatcgacta cccctggttc 780  
 cagaactccc ccgtcatcac cttcctcaac aagaaggacc tgctggagga caatctctg 840

EX05-001patentin.txt

tactcacaca tggaggacta cttccccgag ttcgaagggc cccagcagga cgcccaggcg 900  
 gcgcgggagt tcattcctgaa gatgttagtg gacatgaacc cgcacagcga caagatcatc 960  
 gactcccact tcacgtacgc caccgacacg aagaacatcc gcttcgtggt cgcgcccggtg 1020  
 aaggacacca tcctgcagct cagcctcaag gagtacaacc tggctctga 1068

<210> 6  
 <211> 359  
 <212> PRT  
 <213> Homo sapiens

<400> 6

Met Thr Leu Glu Ser Met Met Ala Cys Cys Leu Ser Asp Glu Val Lys  
 1 5 10 15  
 Glu Ser Lys Arg Ile Asn Ala Glu Ile Glu Lys Gln Leu Arg Arg Asp  
 20 25 30  
 Lys Arg Asp Ala Arg Arg Glu Leu Lys Leu Leu Leu Gly Thr Gly  
 35 40 45  
 Glu Ser Gly Lys Ser Thr Phe Ile Lys Gln Met Arg Ile Ile His Gly  
 50 55 60  
 Ala Gly Tyr Ser Glu Glu Asp Lys Arg Gly Phe Thr Lys Leu Val Tyr  
 65 70 75 80  
 Gln Asn Ile Phe Thr Ala Met Gln Ala Met Ile Arg Ala Met Glu Thr  
 85 90 95  
 Leu Lys Ile Leu Tyr Lys Tyr Glu Gln Asn Lys Ala Asn Ala Leu Leu  
 100 105 110  
 Ile Arg Glu Val Asp Val Glu Lys Val Thr Thr Phe Glu His Gln Tyr  
 115 120 125  
 Val Ser Ala Ile Lys Thr Leu Trp Glu Asp Pro Gly Ile Gln Glu Cys  
 130 135 140  
 Tyr Asp Arg Arg Arg Glu Tyr Gln Leu Ser Asp Ser Ala Lys Tyr Tyr  
 145 150 155 160  
 Leu Thr Asp Val Asp Arg Ile Ala Thr Leu Gly Tyr Leu Pro Thr Gln  
 165 170 175  
 Gln Asp Val Leu Arg Val Arg Val Pro Thr Thr Gly Ile Ile Glu Tyr  
 180 185 190  
 Pro Phe Asp Leu Glu Asn Ile Ile Phe Arg Met Val Asp Val Gly Gly  
 195 200 205

EX05-001patentin.txt

Gln Arg Ser Glu Arg Arg Lys Trp Ile His Cys Phe Glu Asn Val Thr  
 210 215 220

Ser Ile Met Phe Leu Val Ala Leu Ser Glu Tyr Asp Gln Val Leu Val  
 225 230 235 240

Glu Ser Asp Asn Glu Asn Arg Met Glu Glu Ser Lys Ala Leu Phe Arg  
 245 250 255

Thr Ile Ile Thr Tyr Pro Trp Phe Gln Asn Ser Ser Val Ile Leu Phe  
 260 265 270

Leu Asn Lys Lys Asp Leu Leu Glu Asp Lys Ile Leu Tyr Ser His Leu  
 275 280 285

Val Asp Tyr Phe Pro Glu Phe Asp Gly Pro Gln Arg Glu Pro Gln Ala  
 290 295 300

Ala Arg Glu Phe Ile Leu Lys Met Phe Val Asp Leu Asn Pro Asp Ser  
 305 310 315 320

Asp Lys Ile Ile Tyr Ser His Phe Thr Cys Ala Thr Asp Thr Glu Asn  
 325 330 335

Ile Arg Phe Val Phe Ala Ala Val Lys Asp Thr Ile Leu Gln Leu Asn  
 340 345 350

Leu Lys Glu Tyr Asn Leu Val  
 355

<210> 7  
 <211> 355  
 <212> PRT  
 <213> Homo sapiens  
 <400> 7

Met Ala Gly Cys Cys Cys Leu Ser Ala Glu Glu Lys Glu Ser Gln Arg  
 1 5 10 15

Ile ser Ala Glu Ile Glu Arg Gln Leu Arg Arg Asp Lys Lys Asp Ala  
 20 25 30

Arg Arg Glu Leu Lys Leu Leu Leu Leu Gly Thr Gly Glu Ser Gly Lys  
 35 40 45

Ser Thr Phe Ile Lys Gln Met Arg Ile Ile His Gly Ser Gly Tyr Ser  
 50 55 60

Asp Glu Asp Arg Lys Gly Phe Thr Lys Leu Val Tyr Gln Asn Ile Phe  
 65 70 75 80

Thr Ala Met Gln Ala Met Ile Arg Ala Met Asp Thr Leu Arg Ile Gln  
 Page 7

## EX05-001patentin.txt

85

90

95

Tyr Val Cys Glu Gln Asn Lys Glu Asn Ala Gln Ile Ile Arg Glu Val  
 100 105 110

Glu Val Asp Lys Val Ser Met Leu Ser Arg Glu Gln Val Glu Ala Ile  
 115 120 125

Lys Gln Leu Trp Gln Asp Pro Gly Ile Gln Glu Cys Tyr Asp Arg Arg  
 130 135 140

Arg Glu Tyr Gln Leu Ser Asp Ser Ala Lys Tyr Tyr Leu Thr Asp Ile  
 145 150 155 160

Asp Arg Ile Ala Thr Pro Ser Phe Val Pro Thr Gln Gln Asp Val Leu  
 165 170 175

Arg Val Arg Val Pro Thr Thr Gly Ile Ile Glu Tyr Pro Phe Asp Leu  
 180 185 190

Glu Asn Ile Ile Phe Arg Met Val Asp Val Gly Gly Gln Arg Ser Glu  
 195 200 205

Arg Arg Lys Trp Ile His Cys Phe Glu Ser Val Thr Ser Ile Ile Phe  
 210 215 220

Leu Val Ala Leu Ser Glu Tyr Asp Gln Val Leu Ala Glu Cys Asp Asn  
 225 230 235 240

Glu Asn Arg Met Glu Glu Ser Lys Ala Leu Phe Lys Thr Ile Ile Thr  
 245 250 255

Tyr Pro Trp Phe Leu Asn Ser Ser Val Ile Leu Phe Leu Asn Lys Lys  
 260 265 270

Asp Leu Leu Glu Glu Lys Ile Met Tyr Ser His Leu Ile Ser Tyr Phe  
 275 280 285

Pro Glu Tyr Thr Gly Pro Lys Gln Asp Val Arg Ala Ala Arg Asp Phe  
 290 295 300

Ile Leu Lys Leu Tyr Gln Asp Gln Asn Pro Asp Lys Glu Lys Val Ile  
 305 310 315 320

Tyr Ser His Phe Thr Cys Ala Thr Asp Thr Asp Asn Ile Arg Phe Val  
 325 330 335

Phe Ala Ala Val Lys Asp Thr Ile Leu Gln Leu Asn Leu Arg Glu Phe  
 340 345 350

Asn Leu Val

EX05-001patentin.txt

355

<210> 8  
 <211> 374  
 <212> PRT  
 <213> Homo sapiens  
 <400> 8  
 Met Ala Arg Ser Leu Thr Trp Arg Cys Cys Pro Trp Cys Leu Thr Glu  
 1 5 10 15  
 Asp Glu Lys Ala Ala Ala Arg Val Asp Gln Glu Ile Asn Arg Ile Leu  
 20 25 30  
 Leu Glu Gln Lys Lys Gln Asp Arg Gly Glu Leu Lys Leu Leu Leu  
 35 40 45  
 Gly Pro Gly Glu Ser Gly Lys Ser Thr Phe Ile Lys Gln Met Arg Ile  
 50 55 60  
 Ile His Gly Ala Gly Tyr Ser Glu Glu Glu Arg Lys Gly Phe Arg Pro  
 65 70 75 80  
 Leu Val Tyr Gln Asn Ile Phe Val Ser Met Arg Ala Met Ile Glu Ala  
 85 90 95  
 Met Glu Arg Leu Gln Ile Pro Phe Ser Arg Pro Glu Ser Lys His His  
 100 105 110  
 Ala Ser Leu Val Met Ser Gln Asp Pro Tyr Lys Val Thr Thr Phe Glu  
 115 120 125  
 Lys Arg Tyr Ala Ala Ala Met Gln Trp Leu Trp Arg Asp Ala Gly Ile  
 130 135 140  
 Arg Ala Cys Tyr Glu Arg Arg Arg Glu Phe His Leu Leu Asp Ser Ala  
 145 150 155 160  
 Val Tyr Tyr Leu Ser His Leu Glu Arg Ile Thr Glu Glu Gly Tyr Val  
 165 170 175  
 Pro Thr Ala Gln Asp Val Leu Arg Ser Arg Met Pro Thr Thr Gly Ile  
 180 185 190  
 Asn Glu Tyr Cys Phe Ser Val Gln Lys Thr Asn Leu Arg Ile Val Asp  
 195 200 205  
 Val Gly Gly Gln Lys Ser Glu Arg Lys Lys Trp Ile His Cys Phe Glu  
 210 215 220  
 Asn Val Ile Ala Leu Ile Tyr Leu Ala Ser Leu Ser Glu Tyr Asp Gln  
 225 230 235 240

## EX05-001patentin.txt

Cys Leu Glu Glu Asn Asn Gln Glu Asn Arg Met Lys Glu Ser Leu Ala  
 245 250 255

Leu Phe Gly Thr Ile Leu Glu Leu Pro Trp Phe Lys Ser Thr Ser Val  
 260 265 270

Ile Leu Phe Leu Asn Lys Thr Asp Ile Leu Glu Glu Lys Ile Pro Thr  
 275 280 285

Ser His Leu Ala Thr Tyr Phe Pro Ser Phe Gln Gly Pro Lys Gln Asp  
 290 295 300

Ala Glu Ala Ala Lys Arg Phe Ile Leu Asp Met Tyr Thr Arg Met Tyr  
 305 310 315 320

Thr Gly Cys Val Asp Gly Pro Glu Gly Ser Lys Lys Gly Ala Arg Ser  
 325 330 335

Arg Arg Leu Phe Ser His Tyr Thr Cys Ala Thr Asp Thr Gln Asn Ile  
 340 345 350

Arg Lys Val Phe Lys Asp Val Arg Asp Ser Val Leu Ala Arg Tyr Leu  
 355 360 365

Asp Glu Ile Asn Leu Leu  
 370

<210> 9  
 <211> 359  
 <212> PRT  
 <213> Homo sapiens

<400> 9

Met Thr Leu Glu Ser Ile Met Ala Cys Cys Leu Ser Glu Glu Ala Lys  
 1 5 10 15

Glu Ala Arg Arg Ile Asn Asp Glu Ile Glu Arg Gln Leu Arg Arg Asp  
 20 25 30

Lys Arg Asp Ala Arg Arg Glu Leu Lys Leu Leu Leu Gly Thr Gly  
 35 40 45

Glu Ser Gly Lys Ser Thr Phe Ile Lys Gln Met Arg Ile Ile His Gly  
 50 55 60

Ser Gly Tyr Ser Asp Glu Asp Lys Arg Gly Phe Thr Lys Leu Val Tyr  
 65 70 75 80

Gln Asn Ile Phe Thr Ala Met Gln Ala Met Ile Arg Ala Met Asp Thr  
 85 90 95

## EX05-001patentin.txt

Leu Lys Ile Pro Tyr Lys Tyr Glu His Asn Lys Ala His Ala Gln Leu  
 100 105 110  
 Val Arg Glu Val Asp Val Glu Lys Val Ser Ala Phe Glu Asn Pro Tyr  
 115 120 125  
 Val Asp Ala Ile Lys Ser Leu Trp Asn Asp Pro Gly Ile Gln Glu Cys  
 130 135 140  
 Tyr Asp Arg Arg Arg Glu Tyr Gln Leu Ser Asp Ser Thr Lys Tyr Tyr  
 145 150 155 160  
 Leu Asn Asp Leu Asp Arg Val Ala Asp Pro Ala Tyr Leu Pro Thr Gln  
 165 170 175  
 Gln Asp Val Leu Arg Val Arg Val Pro Thr Thr Gly Ile Ile Glu Tyr  
 180 185 190  
 Pro Phe Asp Leu Gln Ser Val Ile Phe Arg Met Val Asp Val Gly Gly  
 195 200 205  
 Gln Arg Ser Glu Arg Arg Lys Trp Ile His Cys Phe Glu Asn Val Thr  
 210 215 220  
 Ser Ile Met Phe Leu Val Ala Leu Ser Glu Tyr Asp Gln Val Leu Val  
 225 230 235 240  
 Glu Ser Asp Asn Glu Asn Arg Met Glu Glu Ser Lys Ala Leu Phe Arg  
 245 250 255  
 Thr Ile Ile Thr Tyr Pro Trp Phe Gln Asn Ser Ser Val Ile Leu Phe  
 260 265 270  
 Leu Asn Lys Lys Asp Leu Leu Glu Glu Lys Ile Met Tyr Ser His Leu  
 275 285  
 Val Asp Tyr Phe Pro Glu Tyr Asp Gly Pro Gln Arg Asp Ala Gln Ala  
 290 295 300  
 Ala Arg Glu Phe Ile Leu Lys Met Phe Val Asp Leu Asn Pro Asp Ser  
 305 310 315 320  
 Asp Lys Ile Asn Tyr Ser His Phe Thr Cys Ala Thr Asp Thr Glu Asn  
 325 330 335  
 Ile Arg Phe Val Phe Ala Ala Val Lys Asp Thr Ile Leu Gln Leu Asn  
 340 345 350  
 Leu Lys Glu Tyr Asn Leu Val  
 355

## EX05-001patentin.txt

<210> 10  
 <211> 355  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (68)..(68)  
 <223> Xaa can be any naturally occurring amino acid

<400> 10

Met Thr Leu Glu Ser Met Met Ala Cys Cys Leu Ser Asp Lys Val Lys  
 1 5 10 15

Glu Ser Lys Arg Ile Asn Ala Glu Ile Gln Lys Gln Leu Arg Gly Asp  
 20 25 30

Lys Arg Asp Ala Arg Arg Gln Leu Lys Leu Leu Leu Leu Leu Thr Gly  
 35 40 45

Glu Ser Gly Lys Ser Thr Phe Ile Lys Gln Met Arg Ile Ile His Gly  
 50 55 60

Ala Gly Tyr Xaa Glu Glu Asp Lys Arg Gly Phe Thr Lys Leu Val Tyr  
 65 70 75 80

Gln Asn Ile Phe Thr Ala Met Gln Ala Met Ile Arg Ala Met Glu Thr  
 85 90 95

Leu Lys Ile Leu Tyr Lys Leu Glu Gln Asn Lys Ala Asn Ala Leu Gln  
 100 105 110

Ile Arg Glu Val Asp Val Glu Lys Val Thr Thr Phe Glu His Arg Tyr  
 115 120 125

Val Ser Ala Ile Lys Thr Leu Trp Asp Asp Pro Gly Ile His Glu Cys  
 130 135 140

Tyr Asp Arg Arg Arg Glu Tyr Gln Leu Ser Asp Ser Ala Lys Tyr Cys  
 145 150 155 160

Val Thr Asp Val Asp Cys Ile Ala Thr Ser Ser Tyr Leu Pro Thr Gln  
 165 170 175

Gln Asp Val Leu Arg Val Arg Val Pro Thr Thr Gly Val Phe Asp Leu  
 180 185 190

Glu Asn Ile Ile Phe Arg Met Ala Asp Val Gly Gly Gln Arg Ser Ala  
 195 200 205

Gln Arg Lys Trp Ile His Cys Phe Glu Asn Leu Thr Ser Ile Pro Phe  
 210 215 220

## EX05-001patentin.txt

Leu Val Ala Leu Ser Glu Tyr Asp Gln Val Leu Val Glu Ser Asp Asn  
225 230 235 240

Glu Asn Arg Met Glu Glu Ser Lys Ala Leu Phe Arg Thr Ile Ile Asp  
245 250 255

Tyr Pro Trp Phe Gln Asn Ser Pro Val Ile Thr Phe Leu Asn Lys Lys  
260 265 270

Asp Leu Leu Glu Asp Asn Ile Leu Tyr Ser His Met Val Asp Tyr Phe  
275 280 285

Pro Glu Phe Glu Gly Pro Gln Gln Asp Ala Gln Ala Ala Arg Glu Phe  
290 295 300

Ile Leu Lys Met Leu Val Asp Met Asn Pro Asp Ser Asp Lys Ile Ile  
305 310 315 320

Asp Ser His Phe Thr Tyr Ala Thr Asp Thr Lys Asn Ile Arg Phe Val  
325 330 335

Phe Ala Ala Val Lys Asp Thr Ile Leu Gln Leu Ser Leu Lys Glu Tyr  
340 345 350

Asn Leu Val  
355

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US05/02734

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : G01N 33/53, 33/566; A01N 61/00; C12Q 1/68  
 US CL : 435/ 6, 7.1; 436/501; 514/1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 U.S. : 435/ 6, 7.1; 436/501; 514/1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
 East

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 MEDLINE, BIOSIS, EMBASE, PUBMED, SCISEARCH, CAPLUS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 20030224406 A1 (COSTA et al.) 04 December 2003 (04.12.2003), whole document.	1-24
A	US 20030064384 A1 (HUNG et al.) 03 April 2003 (03.04.2003), whole document.	1-24
A	Tateishi et al., The NEDD8 system is essential for cell cycle progression and morphogenetic pathway in mice, The Journal of Cell Biology, Volume 155, Number 4, 2001, pages 571-579, whole document.	1-24
A	Cox et al., A Screen for Mutations that Suppress the Phenotype of Drosophila armadillo, the B-Catenin Homolog, Genetics 155: 1725-1740 (August 2000), whole document.	1-24

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

09 May 2005 (09.05.2005)


Date of mailing of the international search report

**24 MAY 2005**

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450

Authorized officer

Gary Counts   
 Telephone No. (703) 308-0196

Facsimile No. (703) 305-3230